PATH: Form 990, tax year 2020
View the entire original 990 at ProPublica ↗
- Organization
- PATH (EIN 91-1157127)
- Tax period
- 2020-01-01 to 2020-12-31
- Filed
- 2021-11-12
- IRS object ID
- 202103169349312140
- Schema version
- 2020v4.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2021-11-12T16:58:13-06:00 | ReturnTs |
| Tax Period End | 2020-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 521392008 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | GELMAN ROSENBERG & FREEDMAN | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4550 MONTGOMERY AVE SUITE 800N | AddressLine1Txt |
| City | BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 208142930 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2020-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 911157127 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PATH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | PATH | BusinessNameControlTxt |
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE NO 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | KELLY PRIESTLEY | PersonNm |
| Person Title | CONTROLLER | PersonTitleTxt |
| Phone | 2062853500 | PhoneNum |
| Signature | 2021-11-12 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Signing Officer SigningOfficerGrp
Person Full Name PersonFullName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person First | KELLY | PersonFirstNm |
| Person Last | PRIESTLEY | PersonLastNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| SSN | 999009999 | SSN |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | RICHARD J LOCASTRO CPA | PreparerPersonNm |
| PTIN | P00288314 | PTIN |
| Phone | 3019519090 | PhoneNum |
Additional Filer Information AdditionalFilerInformation
Trusted Customer TrustedCustomerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Trusted Customer | 2 | TrustedCustomerCd |
| Authentication Assurance Level | AAL1 | AuthenticationAssuranceLevelCd |
| Identity Assurance Level | IAL1 | IdentityAssuranceLevelCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2020 | TaxYr |
| Build TS | 2022-09-23 18:48:47Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | KELLY PRIESTLEY | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE NO 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $357,796,602 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.PATH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1981 | FormationYr |
| Legal Domicile State | WA | LegalDomicileStateCd |
| Activity Or Mission | SEE PART III, LINE 1. | ActivityOrMissionDesc |
| Voting Members Governing Body | 15 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 15 | VotingMembersIndependentCnt |
| Total Employee | 714 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $286,808,545 | PYContributionsGrantsAmt |
| CY Contributions Grants | $287,454,383 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $2,038 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $0 | CYProgramServiceRevenueAmt |
| PY Investment Income | $6,723,428 | PYInvestmentIncomeAmt |
| CY Investment Income | $12,502,251 | CYInvestmentIncomeAmt |
| PY Other Revenue | $836,870 | PYOtherRevenueAmt |
| CY Other Revenue | $1,030,112 | CYOtherRevenueAmt |
| PY Total Revenue | $294,370,881 | PYTotalRevenueAmt |
| CY Total Revenue | $300,986,746 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $55,619,080 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $67,994,827 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $131,590,498 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $132,096,396 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $2,409,886 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $105,099,261 | PYOtherExpensesAmt |
| CY Other Expenses | $92,968,260 | CYOtherExpensesAmt |
| PY Total Expenses | $292,308,839 | PYTotalExpensesAmt |
| CY Total Expenses | $293,059,483 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $2,062,042 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $7,927,263 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $243,064,155 | TotalAssetsBOYAmt |
| Total Assets EOY | $283,556,203 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $204,045,574 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $234,982,056 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $39,018,581 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $48,574,147 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O) | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $115,045,810 | ExpenseAmt |
| Grant | $20,527,002 | GrantAmt |
| Desc | GLOBAL HEALTH PROGRAMS: PATH'S GLOBAL HEALTH PROGRAMS DIVISION IS RESPONSIBLE FOR PATH'S SCIENTIFIC EXPERTISE IN MALARIA AND NEGLECTED TROPICAL DISEASES; HIV AND TUBERCULOSIS; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; AND NONCOMMUNICABLE DISEASES. THE DIVISION ALSO OVERSEES PATH'S WORK IN HEALTH SYSTEMS INNOVATION AND DELIVERY, AND MANAGES OUR COUNTRY OFFICES.(CONTINUED ON SCHEDULE O)MALARIA AND NEGLECTED TROPICAL DISEASESPATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS ACROSS THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. OUR MALARIA AND NEGLECTED TROPICAL DISEASES PROGRAM INCLUDES MORE THAN 100 PATH STAFF MEMBERS IN MORE THAN TEN COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DESIGNING NEW STRATEGIES AND DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. PATH-PIONEERED APPROACHES HAVE CONTRIBUTED TO REMARKABLE PROGRESS IN MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2020, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA TOWARD THEIR MALARIA ELIMINATION GOALS. MACEPA'S WORK INCLUDED EVALUATING THE LATEST, MOST SENSITIVE DIAGNOSTIC TESTS; ESTABLISHING RAPID REPORTING SYSTEMS; AND CONTINUING TO SUPPORT POPULATION-WIDE, DRUG-BASED STRATEGIES SUCH AS MASS DRUG ADMINISTRATION. WITH A NEW GRANT FROM THE BILL & MELINDA GATES FOUNDATION, MACEPA BEGAN IDENTIFYING OPPORTUNITIES IN ADDITIONAL HIGH-MALARIA-BURDEN GEOGRAPHIES SUCH AS THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), MALAWI, MALI, AND NIGERIA.PATH WAS ALSO AWARDED AN ADD-ON TO OUR PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES (PAMO), FUNDED BY THE US PRESIDENT'S MALARIA INITIATIVE (PMI). CALLED PAMO PLUS, THE PROJECT CONTINUES ITS PREDECESSOR'S MISSION OF ASSISTING THE GOVERNMENT OF ZAMBIA TO ELIMINATE MALARIA WITHIN ITS BORDERS. IN 2020, PAMO PROVIDED TECHNICAL SUPPORT AND MENTORSHIP TO MORE THAN 2,000 HEALTH CARE PROVIDERS AND TRAINED 1,098 COMMUNITY HEALTH WORKERS AND THEIR 272 SUPERVISORS IN COMMUNITY-LEVEL CASE MANAGEMENT AND SURVEILLANCE. PAMO/PAMO PLUS ALSO SUPPORTED THE DISTRIBUTION OF 122,602 INSECTICIDE-TREATED BEDNETS, ORGANIZED SOCIAL BEHAVIOR CHANGE ACTIVITIES (INCLUDING IN SCHOOLS), AND PROVIDED TECHNICAL AND MATERIAL SUPPORT FOR DATA QUALITY AUDITS IN HEALTH FACILITIES.PATH CONTINUED TO EVALUATE NEW VECTOR CONTROL TOOLS IN 2020 WITH OUR PARTNERS UNDER PMI VECTORLINK, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT'S (USAID'S) FLAGSHIP MALARIA VECTOR CONTROL PROJECT. SIMILARLY, UNDER THE NEW NETS PROJECT FUNDED BY UNITAID AND THE GLOBAL FUND TO FIGHT AIDS, TUBERCULOSIS AND MALARIA, WE HELPED GENERATE EVIDENCE FOR THE ADOPTION OF BEDNETS EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. IN ZAMBIA, PATH LED THE DESIGN AND IMPLEMENTATION OF LABORATORY AND FIELD ACTIVITIES TO TEST ANOTHER NEW TOOL FOR MALARIA VECTOR CONTROL, THE ATTRACTIVE TARGETED SUGAR BAIT (ATSB); WE ALSO COORDINATED PARTNERS WORKING ON ATSB RESEARCH IN KENYA, MALI, AND ZAMBIA, TOGETHER WITH ISRAEL-BASED MANUFACTURER WESTHAM LTD. AND UK-BASED FUNDER INNOVATIVE VECTOR CONTROL CONSORTIUM. IN ADDITION, PATH LED A USAID INITIATIVE TO SUPPORT US GOVERNMENT INVESTMENTS IN MALARIA OPERATIONAL RESEARCH AND PROGRAM EVALUATION. UNDER THE PMI INSIGHTS PROJECT, PATH COORDINATED THE WORK OF SEVERAL PARTNERS TO STRENGTHEN POLICIES, STRATEGIES, AND GUIDELINES FOR MALARIA CONTROL AND ELIMINATION INTERVENTIONS. IN SENEGAL AND DRC, PATH BEGAN WORK TO INTEGRATE THE DATA VISUALIZATION DASHBOARDS OF THE NATIONAL EMERGENCY OPERATIONS CENTERS AND NATIONAL MALARIA CONTROL PROGRAMS AND DEVELOP IN-COUNTRY CAPACITY FOR DATA USE. THESE EFFORTS HELPED BOTH COUNTRIES RESPOND TO COVID-19 AND MITIGATE THE VIRUS' IMPACT ON MALARIA CONTROL AND ELIMINATION. PATH AND A PRIVATE-SECTOR TECHNOLOGY PARTNER, BLUESQUARE, SUPPORTED THE DRC MINISTRY OF HEALTH (MOH) TO STRENGTHEN COVID-19 CASE TRACKING AND CONTACT TRACING.AT THE ONSET OF COVID-19, THE PATH LABORATORY TEAM IN ZAMBIA PIVOTED FROM MALARIA TO WHOLE GENOME SEQUENCING OF SARS-COV-2 (THE VIRUS RESPONSIBLE FOR COVID-19) THROUGH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION AND IN COLLABORATION WITH THE UNIVERSITY OF ZAMBIA SCHOOL OF VETERINARY MEDICINE. THE LABORATORY'S WORK ENABLED IDENTIFICATION OF THE BETA (B.1.351) VARIANT OF CONCERN IN ZAMBIA, WHICH WAS ASSOCIATED WITH A MAJOR SECOND WAVE OF COVID-19 IN THE COUNTRY. THE LABORATORY'S WORK ALSO LED TO ESTABLISHMENT OF A NATIONAL SPECIMEN COLLECTION SYSTEM THROUGH THE ZAMBIA NATIONAL PUBLIC HEALTH INSTITUTE.THE VIVACCESS PROJECT, WHICH FOCUSES ON RADICAL CURE (ELIMINATION OF DORMANT LIVER-STAGE PARASITES) OF PLASMODIUM VIVAX MALARIA, CONTINUED TO SUPPORT INTRODUCTION OF G6PD TESTS AND OTHER RADICAL CURE PRODUCTS IN BRAZIL, CAMBODIA, COLOMBIA, ETHIOPIA, INDIA, LAOS, MYANMAR, PERU, THAILAND, AND VIETNAM. VIVACCESS ENGAGED WITH NORMATIVE POLICY BODIES SUCH AS THE WORLD HEALTH ORGANIZATION (WHO), PROMOTED MULTISTAKEHOLDER DISCUSSIONS THROUGH REGIONAL AND GLOBAL EVENTS, AND MUCH MORE. (ADDITIONAL WORK IN MALARIA IS COVERED IN THE CENTER FOR VACCINE INNOVATION AND ACCESS SECTION.)PATH'S EFFORTS TO ELIMINATE NEGLECTED TROPICAL DISEASES CONTINUED IN 2020 IN THE DRC, WHERE WE WORKED TO COMBAT HUMAN AFRICAN TRYPANOSOMIASIS (HAT, OR "SLEEPING SICKNESS") IN COLLABORATION WITH THE COUNTRY'S NATIONAL PROGRAM FOR THE CONTROL OF HAT (PNLTHA). WITH FUNDING FROM THE BILL & MELINDA GATES FOUNDATION, PATH PROVIDED LOGISTICAL AND OPERATIONAL SUPPORT TO THE PNLTHA IN ACTIVE AND PASSIVE CASE DETECTION AND VECTOR CONTROL. WE ALSO SUPPORTED ADVOCACY, SENSITIZATION, AND PROMOTION ACTIVITIES TO STRENGTHEN HAT ELIMINATION EFFORTS AT THE NATIONAL, PROVINCIAL, AND COMMUNITY LEVELS. IN INDIA, PATH CONTINUED TO PROVIDE STRATEGIC TECHNICAL ASSISTANCE AT THE NATIONAL, STATE, AND SUB-STATE LEVELS. IN THE STATE OF UTTAR PRADESH, WE HELPED ENSURE TRANSMISSION OF VISCERAL LEISHMANIASIS STAYED AT OR BELOW ELIMINATION LEVEL IN ENDEMIC DISTRICTS THROUGH HIGH-QUALITY SURVEILLANCE, ACTIVE CASE DETECTION, AND VECTOR CONTROL. PATH ALSO PROVIDED TECHNICAL ASSISTANCE FOR LYMPHATIC FILARIASIS (ELEPHANTIASIS) ELIMINATION THROUGH MASS DRUG ADMINISTRATION AND HELPED ESTABLISH A TECHNICAL SUPPORT UNIT FOR DENGUE-CHIKUNGUNYA CONTROL AND MALARIA ELIMINATION. HIV AND TUBERCULOSISPATH'S HIV AND TUBERCULOSIS (TB) PROGRAMMING REACHES GENERAL POPULATIONS AS WELL AS KEY POPULATIONS AFFECTED BY HIV/TB.IN 2020, AS THE COVID-19 RESPONSE HINDERED ACCESS TO HEALTH FACILITIES IN MANY COUNTRIES, PATH MOVED RAPIDLY TO MINIMIZE THE IMPACT ON HIV AND TB SERVICES. PATH USED AN APPROACH OF PROTECT-MITIGATE-SUPPORT: UNDER THE "PROTECT" PILLAR, WE EQUIPPED AND TRAINED FRONTLINE HEALTH CARE PROVIDERS TO TRIAGE AND DELIVER SERVICES TO PEOPLE WITH COVID-19 EXPOSURE OR SYMPTOMS. UNDER THE "MITIGATE" PILLAR, WE ADAPTED WHERE AND HOW HIV AND TB SERVICES WERE OFFERED, SHIFTING TOWARD VIRTUAL, COMMUNITY, AND PRIVATE-SECTOR DELIVERY MODALITIES AND MULTI-MONTH DRUG DISPENSING TO REDUCE THE NEED FOR CLINIC VISITS. UNDER THE "SUPPORT" PILLAR, WE USED EXISTING HIV AND TB PLATFORMS TO DISSEMINATE INFORMATION ON COVID-19, AND WE ADAPTED TB SCREENING PROTOCOLS TO INCLUDE SCREENING AND TRIAGE FOR COVID-19 (AND VICE VERSA). IN THE DRC, UNDER THE USAID-FUNDED INTEGRATED HIV/AIDS PROJECT, PATH INTRODUCED ASSISTED HIV SELF-TESTING (HIVST) VIA PHARMACISTS, ALTERNATIVE MEDICINE PROVIDERS, AND COMMUNITY HEALTH WORKERS. WE TESTED APPROXIMATELY 180,000 PEOPLE, ENROLLED AROUND 12,400 NEWLY IDENTIFIED PEOPLE LIVING WITH HIV (PLHIV) ON ANTIRETROVIRAL THERAPY (ART), AND SUPPORTED MORE THAN 43,800 INDIVIDUALS TO CONTINUE TREATMENT. IN WESTERN KENYA, UNDER THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF-FUNDED AFYA ZIWANI PROJECT, PATH EVOLVED OUR APPROACH, PARTICULARLY FOR HIV-NEGATIVE AGYW. THE PROJECT CREATED WHATSAPP-BASED VIRTUAL SAFE SPACES AND MOBILE, HOME-BASED SAFE SPACES TO ENSURE AGYW CONTINUED TO RECEIVE INFORMATION, COUNSELING, AND OTHER SERVICES DURING THE COVID-19 PANDEMIC; WE ALSO USED THESE SPACES TO DISSEMINATE INFORMATION ON COVID-19. THE PROJECT HOME-DELIVERED APPROXIMATELY 800 HIV PRE-EXPOSURE PROPHYLAXIS REFILLS AND MORE THAN 8,000 HIVST KITS FOR AGYW, WITH NO HIV-POSITIVE RESULTS. ACROSS ALL POPULATION GROUPS, AFYA ZIWANI TESTED MORE THAN 140,000 PEOPLE FOR HIV, LINKED ABOUT 3,500 NEWLY IDENTIFIED PLHIV TO ART, AND SUPPORTED A COHORT OF 25,600 PEOPLE ON TREATMENT. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $92,606,261 | ExpenseAmt |
| Grant | $34,739,083 | GrantAmt |
| Desc | ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATH AND DISEASE WORLDWIDE. IN RESPONSE TO THE COVID-19 PANDEMIC, PATH MOBILIZED QUICKLY TO DEPLOY OUR END-TO-END IMMUNIZATION EXPERTISE. WE PROVIDED POLICY AND FINANCIAL ADVICE TO GAVI ON DESIGN OF THE COVAX FACILITY WITH THE GOAL OF EQUITABLE COVID-19 VACCINE ACCESS AND DELIVERY WORLDWIDE. WE SECURED INITIAL FUNDING TO ADVANCE A LOW-COST COVID-19 VACCINE CANDIDATE (NDV-HXP-S) BASED ON TECHNOLOGIES DEVELOPED BY THE ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI AND THE UNIVERSITY OF TEXAS AT AUSTIN THAT IS TARGETED FOR EMERGING COUNTRY VACCINE MANUFACTURERS. ACROSS THE COVID-19 VACCINE DEVELOPMENT ECOSYSTEM, WE SUPPORTED VACCINE DEVELOPMENT AND CLINICAL SITE READINESS; PROVIDED CHEMISTRY, MANUFACTURING, AND CONTROL EXPERTISE TO MANUFACTURERS; AND LENT OUR CLINICAL, TECHNICAL, AND REGULATORY EXPERTISE TO DEVELOPERS AND COVID-19 CONSORTIA.IN 2020, PATH CONTINUED TO PROVIDE TECHNICAL SUPPORT TO POLIO VACCINE MANUFACTURERS AND ADVANCE RESEARCH ON NEW INACTIVATED POLIO VACCINE AND ORAL POLIO VACCINE CANDIDATES. THE NOVEL ORAL POLIO VACCINE AGAINST TYPE 2 POLIOVIRUS (NOPV2) ACHIEVED A MAJOR MILESTONE WHEN IT BECAME THE FIRST VACCINE TO RECEIVE A WHO EMERGENCY USE LISTING (EUL). AS THE CONVENOR OF THE NOPV2 CONSORTIUM, PATH CONTRIBUTED KEY EVIDENCE AND SUPPORTED THE MANUFACTURER'S SUCCESSFUL EUL APPLICATION. THROUGHOUT 2020, PATH AND OUR COUNTRY PARTNERS EXPANDED COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINATION AND DEVELOPED AND DISSEMINATED EVIDENCE TO SUPPORT JE VACCINE DECISION-MAKING. WRAPPING UP A REMARKABLE 17-YEAR GLOBAL PARTNERSHIP, PATH COMPLETED TWO STUDIES EXAMINING JE VACCINE DURATION OF PROTECTION AND CO-ADMINISTRATION AND FINALIZED A SUITE OF MATERIALS OUTLINING THE LESSONS AND STORY OF JE VACCINATION EFFORTS. ALSO IN 2020, WE CONTINUED A PIVOTAL, PHASE 3 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS CONJUGATE VACCINE. THE VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A GROUNDBREAKING VACCINE AGAINST SEROGROUP A MENINGOCOCCAL MENINGITIS THAT WAS DEVELOPED THROUGH AN EARLIER PATH PARTNERSHIP. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. AS THE FIRST VACCINE TO TARGET SEROGROUP X, THE VACCINE HAS THE POTENTIAL TO ELIMINATE MENINGITIS EPIDEMICS FROM AFRICA'S "MENINGITIS BELT" REGION. WE ALSO CONTRIBUTED TECHNICAL AND STRATEGIC EXPERTISE TO THE GLOBAL "DEFEATING MENINGITIS BY 2030" INITIATIVE, WHICH CULMINATED IN WORLD HEALTH ASSEMBLY ADOPTION OF THE FIRST-EVER RESOLUTION ON MENINGITIS PREVENTION AND CONTROL AND ENDORSEMENT OF A GLOBAL ROAD MAP TO DEFEAT MENINGITIS.TO PREVENT MALARIA, PATH ACCELERATED THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. FOR EXAMPLE, WE WORKED WITH WHO AND OTHER PARTNERS, INCLUDING THE MINISTRIES OF HEALTH IN GHANA, KENYA, AND MALAWI, TO INTRODUCE THE WORLD'S FIRST MALARIA VACCINE, KNOWN AS RTS,S, IN SELECTED AREAS OF THOSE COUNTRIES. WE ALSO CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO FURTHER AID MALARIA ELIMINATION EFFORTS BY STRETCHING LIMITED VACCINE SUPPLIES AND PROTECTING AS MANY PEOPLE AS POSSIBLE. ADDITIONALLY, WORK CONTINUED ON EFFORTS TO IDENTIFY IMMUNE CORRELATES OF PROTECTION AND STUDY THE USE OF MONOCLONAL ANTIBODIES TO COMBAT MALARIA. IN 2020, PATH RECEIVED A FIVE-YEAR GRANT FROM USAID TO ADVANCE PRE-ERYTHROCYTIC, BLOOD-STAGE, AND COMBINATION MALARIA VACCINE CANDIDATE APPROACHES.THE DEFEAT DIARRHEAL DISEASE (DEFEATDD) INITIATIVE CONTINUED ITS ROLE AS A DIGITAL HUB FOR INFORMATION ON PREVENTING AND TREATING CHILDHOOD DIARRHEAL DISEASE. A MAJOR FOCUS OF 2020 WAS A CAMPAIGN TO MAINTAIN CHILD HEALTH INVESTMENTS DURING THE COVID-19 PANDEMIC, INCLUDING STEADY ACCESS TO ESSENTIAL MEDICINES AND ROUTINE IMMUNIZATION. IN ONGOING EFFORTS TO SUPPORT LOCAL VACCINE PRODUCTION, PATH SUPPORTED VIETNAM-BASED MANUFACTURER POLYVAC TO COMPLETE CLINICAL TRIALS FOR THE LIQUID FORMULATION OF ROTAVIN VACCINE. OUR PHASE 3 STUDY FOUND THAT ROTAVIN IS AS SAFE AND IMMUNOGENIC AS THE CURRENTLY LICENSED FROZEN FORMULATION, ROTAVIN-M1. WE COMPLETED THE CLINICAL PHASE OF A PHASE 1 STUDY IN THE UNITED STATES OF A NOVEL, INJECTABLE SUBUNIT SHIGELLA VACCINE CANDIDATE AND INITIATED FOLLOW-ON EXPLORATORY IMMUNOLOGY ANALYSES USING SAMPLES FROM THE STUDY. AND WE CONTINUED TO HELP INTRODUCE AND ADVANCE ACCESS TO CURRENTLY AVAILABLE ROTAVIRUS VACCINES.PATH CONTINUED TO ADVANCE PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, THE LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. WE SUPPORTED INVENTPRISE, A BIOTECHNOLOGY COMPANY, AS IT WORKS TO DEVELOP A MULTIVALENT, CONJUGATE VACCINE FOR LOW- AND MIDDLE-INCOME COUNTRIES. THE INTENDED RECIPIENTS ARE PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. AS PART OF THE TYPHOID VACCINE ACCELERATION CONSORTIUM, PATH WORKED TO ADVANCE TYPHOID CONJUGATE VACCINE (TCV) INTRODUCTION IN GAVI-ELIGIBLE COUNTRIES. WITH OUR SUPPORT, THE GOVERNMENTS OF MALAWI AND NEPAL MADE THE DECISION TO INTRODUCE TCV AND SUCCESSFULLY APPLIED FOR ASSISTANCE FROM GAVI. PATH ALSO WORKED WITH THE GOVERNMENT OF KENYA ON ITS DECISION TO INTRODUCE TCV AND BEGIN PLANNING. TO ACCOUNT FOR CHALLENGES BROUGHT ON BY THE COVID-19 PANDEMIC, WE HELPED THE GOVERNMENTS OF LIBERIA, PAKISTAN, AND ZIMBABWE ADJUST THEIR TCV CAMPAIGNS.ALSO IN 2020, PATH CONTINUED TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO ANALYZE EVIDENCE ON SINGLE-DOSE HPV VACCINATION. FOR COUNTRIES WITH FINANCIAL, LOGISTICAL, OR OTHER BARRIERS TO INTRODUCTION, A SINGLE-DOSE REGIMEN COULD BE TRANSFORMATIVE. AMONG OTHER ASSISTANCE, OUR GLOBAL TEAM AND PARTNERS HELPED GAVI-ELIGIBLE COUNTRIES RESPOND TO THE COVID-19 PANDEMIC BY PIVOTING HPV VACCINATION PROGRAMS TO REACH OUT-OF-SCHOOL GIRLS.DRUG DEVELOPMENTTHROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. OVER THE YEARS, OUR WORK HAS ADVANCED SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE-FROM EARLY RESEARCH TO INTRODUCTION.IN 2020, WE COMPLETED A PHASE 2 PROOF-OF-CONCEPT CLINICAL TRIAL OF IOWH032, A NOVEL ANTISECRETORY DRUG CANDIDATE FOR THE TREATMENT OF CHOLERA. WHILE IOWH032 WAS NOT EFFICACIOUS IN THIS STUDY, WE LEARNED IMPORTANT LESSONS FOR FUTURE DRUG TRIALS AND CONTINUE TO EXPLORE OTHER USES OF THIS COMPOUND, INCLUDING FOR TREATMENT OF COVID-19, CYSTIC FIBROSIS, AND POTENTIALLY OTHER INDICATIONS.IN ADDITION, WE CONTINUED OUR WORK ON DEVELOPING NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, A DEADLY DIARRHEA-CAUSING PARASITE FOR WHICH NO HIGHLY EFFECTIVE TREATMENT IS AVAILABLE. WE CONDUCTED KEY PRECLINICAL STUDIES AND SELECTED A COMPOUND FOR LARGE-ANIMAL EFFICACY TRIALS.THE DIARRHEA INNOVATIONS GROUP, AN INTERNATIONAL NETWORK OF CHILD HEALTH STAKEHOLDERS HOUSED WITHIN AND CO-CHAIRED BY PATH, CONTINUED TO ADVOCATE IN SUPPORT OF A LIFESAVING TREATMENT FOR DIARRHEA IN CHILDREN: THE USE OF CO-PACKAGED ORAL REHYDRATION SOLUTION AND ZINC, RECOGNIZED BY WHO AS AN ESSENTIAL MEDICINE. INCREASED ACCESS TO THIS TREATMENT COULD ACCELERATE PROGRESS TOWARD CHILD HEALTH GOALS.WITH OUR MANUFACTURING PARTNER QUANSYS BIOSCIENCES, WE MOVED TOWARD COMMERCIALIZATION OF A NEW TOOL FOR ASSESSING ENVIRONMENTAL ENTERIC DYSFUNCTION-AN INTESTINAL DISORDER RESPONSIBLE FOR A SIGNIFICANT PORTION OF THE GROWTH STUNTING OF APPROXIMATELY 140 MILLION CHILDREN WORLDWIDE. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $32,223,655 | ExpenseAmt |
| Grant | $7,574,230 | GrantAmt |
| Desc | TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION: PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION (TAMI) DIVISION IS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT MEDICAL DEVICES, HEALTH TECHNOLOGIES, DIAGNOSTICS, AND IN-COUNTRY "IMPACT LABS" THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. TAMI ALSO MANAGES PATH'S WORK IN MARKET DYNAMICS AND DIGITAL AND DATA EXCELLENCE.(CONTINUED ON SCHEDULE O)MEDICAL DEVICES AND HEALTH TECHNOLOGIESTHE MEDICAL DEVICES AND HEALTH TECHNOLOGIES (MDHT) PROGRAM WITHIN TAMI IS PATH'S PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, INTRODUCE, AND SCALE UP AFFORDABLE INNOVATIONS TO IMPROVE THE HEALTH OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES.MILESTONES IN 2020 INCLUDED BEGINNING THE WORLD'S FIRST FREEZE-PREVENTIVE COLD BOX EVALUATION IN NEPAL; COMPLETING A THREE-YEAR INTRODUCTION AND SCALE-UP OF 7.1 PERCENT CHLORHEXIDINE FOR UMBILICAL CORD CARE IN FRANCOPHONE WEST AFRICA; RECEIVING REGULATORY APPROVAL IN GHANA AND KENYA FOR THE ELLAVI UTERINE BALLOON TAMPONADE-A PATH-DEVELOPED, LIFESAVING MEDICAL DEVICE FOR POSTPARTUM HEMORRHAGE; AND SERVING AS A KEY PARTNER ON THE GAVI-LED VACCINE INNOVATION PRIORITIZATION STRATEGY.MDHT ALSO ADDRESSED THE COVID-19 PANDEMIC: ONE EFFORT AIMED TO ACCELERATE EQUITABLE GLOBAL ACCESS TO COVID-19 VACCINES THROUGH A COLLABORATION WITH UNICEF AND THE COALITION FOR EPIDEMIC PREPAREDNESS INNOVATIONS. WORKING CLOSELY WITH PATH'S CENTER FOR VACCINE INNOVATION AND ACCESS, MDHT ASSESSED THE GLOBAL SUPPLY CHAIN FOR VACCINE COMPONENTS, VACCINE MANUFACTURING CAPACITY, SYRINGE AVAILABILITY, AND COLD CHAIN AND ULTRA-COLD CHAIN CAPACITY. WE ALSO ASSESSED COVID-19 VACCINE COLLATERAL MATERIALS AND INFORMATION-FOR EXAMPLE, NEW PACKAGING AND DELIVERY TECHNOLOGIES, WHO LABELING GUIDELINES, AND E-LEARNING MODULES.MDHT'S LIVING LABS INITIATIVE USED HUMAN-CENTERED DESIGN METHODS IN KENYA AND ZAMBIA TO IDENTIFY CHALLENGES AND PROPOSE SOLUTIONS TO THE MANY OBSTACLES IMMUNIZATION WORKERS FACE. IN KENYA, THE LIVING LABS TEAM ENGAGED HEALTH CARE WORKERS TO IDENTIFY CHALLENGES IN MANAGING POSTPARTUM HEMORRHAGE AND PRIORITIZE SOLUTIONS FOR GOVERNMENT RESPONSE. IN 2020, MDHT STAFF PRODUCED NINE PEER-REVIEWED JOURNAL ARTICLES AND RESEARCH REPORTS ON TOPICS RANGING FROM FREEZE-DRIED TABLETS FOR ORAL VACCINE DELIVERY TO CHLORHEXIDINE FOR FACILITY-BASED UMBILICAL CORD CARE.LAST, A CONSULTANT HIRED BY THE PATH SOUTH AFRICA IMPACT LAB WORKED CLOSELY WITH THE GLOBAL HEALTH INNOVATION ACCELERATOR/SOUTH AFRICAN MEDICAL RESEARCH COUNCIL ON A MEDICAL DEVICE LANDSCAPING ACTIVITY DESIGNED TO ACCELERATE PRODUCTION AND INTRODUCTION OF NOVEL HEALTH TECHNOLOGIES.DIAGNOSTICSPATH'S DIAGNOSTICS PROGRAM ADVANCES EQUITABLE AND SUSTAINABLE ACCESS TO AFFORDABLE, QUALITY-ASSURED DIAGNOSTICS FOR BETTER DIAGNOSIS AND TREATMENT IN LOW-RESOURCE SETTINGS.IN 2020, OUR PIONEERING WORK INCLUDED DEVELOPING, VALIDATING, EVALUATING, AND COMMERCIALIZING TESTS, REFERENCE ASSAYS, AND TOOLS; CONDUCTING LABORATORY PERFORMANCE EVALUATIONS AND CLINICAL STUDIES TO INFORM PATIENT CARE; FACILITATING A G6PD OPERATIONAL RESEARCH COMMUNITY OF PRACTICE; AND PUBLISHING 15 PEER-REVIEWED JOURNAL ARTICLES.THE DIAGNOSTICS TEAM RAPIDLY RESPONDED TO THE GLOBAL COVID-19 PANDEMIC WITH LABORATORY-BASED ACTIVITIES TO SUPPORT DIAGNOSTIC DEVELOPERS. THIS INCLUDED CREATING A BIOREPOSITORY OF QUALIFIED COVID-19 CLINICAL SAMPLES TO ACCELERATE THE DEVELOPMENT AND VALIDATION OF NEW COVID-19 DIAGNOSTIC TESTS (PROVIDED FREE OF CHARGE TO DEVELOPERS INTENDING TO SUPPLY GLOBAL MARKETS); CREATING FIVE DIGITAL, INTERACTIVE COVID-19 DIAGNOSTICS DASHBOARDS THAT AGGREGATE AND VISUALIZE PUBLICLY AVAILABLE INFORMATION ON THE DEVELOPMENT, SUPPLY, REGULATORY APPROVAL, AND PERFORMANCE OF COVID-19 DIAGNOSTIC TESTS (TO SUPPORT PRODUCT SELECTION AND PROCUREMENT DECISIONS WORLDWIDE); CONDUCTING IN-HOUSE EVALUATIONS OF NEW COMMERCIAL RAPID DIAGNOSTIC TESTS TO VERIFY PERFORMANCE CLAIMS AND FIT-FOR-PURPOSE IN INTERNATIONAL SETTINGS; ENSURING THE QUALITY OF COVID-19 RAPID DIAGNOSTIC TESTS WITH A BENCHMARKING PANEL THAT ENABLES UNBIASED, COMPARATIVE EVALUATIONS BETWEEN COVID-19 TESTS; SUPPORTING THE NATIONAL RESPONSE IN INDONESIA, MALAWI, NEPAL, AND PAKISTAN WITH ENVIRONMENTAL SURVEILLANCE DATA COLLECTION PROJECTS TO DETECT AND QUANTIFY THE PRESENCE OF SARS-COV-2 IN IMPACTED WASTEWATER; AND ENSURING THAT COVID-19 POINT-OF-CARE TESTS ARE SUITABLE FOR CLINICAL AND OPERATIONAL STUDIES IN BRAZIL.IN PARTNERSHIP WITH THE UNIVERSITY OF QUEENSLAND, THE DIAGNOSTICS TEAM SUPPORTED THE COMMERCIALIZATION OF CUSTOM MALARIA PROTEINS TO FACILITATE PERFORMANCE BENCHMARKING OF RAPID, ACCURATE, AND SPECIES-SPECIFIC MALARIA DIAGNOSTIC TESTS.THE TEAM ALSO SUBMITTED REGULATORY DOSSIERS FOR THE SD BIOSENSOR STANDARD G6PD TEST, WHICH GUIDES THE TREATMENT OF PLASMODIUM VIVAX MALARIA, TO THE AUSTRALIAN THERAPEUTIC GOODS ADMINISTRATION, THE US FOOD AND DRUG ADMINISTRATION, AND WHO FOR PREQUALIFICATION. IN 2020, NEARLY 75,000 OF THESE TESTS WERE DISTRIBUTED TO 30 COUNTRIES.INDIA IMPACT LABINDIA HAS A RICH INNOVATION ECOSYSTEM WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS FOCUSED ON DEVELOPING PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE. PATH'S INDIA IMPACT LAB, A PARTNERSHIP WITH TATA TRUSTS AND THE INDIAN INSTITUTE OF TECHNOLOGY DELHI, IS A PLATFORM TO ENABLE LATE-STAGE MEDICAL TECHNOLOGY INNOVATIONS TO ACHIEVE MARKET ENTRY, ADOPTION, AND SCALE. THE IMPACT LAB PARTNERS WITH TOP INDIAN TECHNOLOGY AND BUSINESS INCUBATORS IN THE LIFE SCIENCE AND HEALTH CARE INDUSTRIES. IN 2020, THE IMPACT LAB LED PATH'S PARTNERSHIP WITH THE CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS, A PUBLIC-PRIVATE INITIATIVE THAT LAUNCHED THE COVID-19 INNOVATIONS DEPLOYMENT ACCELERATOR (C-CIDA) IN MARCH 2020. C-CIDA HELPS FAST-TRACK INNOVATIONS IN SCREENING, DIAGNOSIS, TREATMENT, MONITORING, CARE, AND MANAGEMENT OF COVID-19. THE IMPACT LAB CONTINUED TO SUPPORT THE MARKET ACCESS PROGRAM OF THE INDIA NATIONAL HEALTH AUTHORITY AND PARTNERED WITH XYNTEO INDIA ON PROJECT TEJ, AN INITIATIVE OF THE TELANGANA STATE GOVERNMENT AND MEDTECH CONNECT TO ACCELERATE INDIAN MEDICAL TECHNOLOGY INNOVATIONS. IN ADDITION, THE IMPACT LAB MANAGED A PIPELINE OF INNOVATIONS BEING EXPLORED FOR INTEGRATION WITH PRIMARY HEALTH CARE, IMMUNIZATION, NUTRITION, TB, COVID-19, FAMILY PLANNING, AND REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH PROGRAMS.THE IMPACT LAB ALSO CONTINUED ITS CROSSCUTTING SUPPORT OF VARIOUS PROGRAMS AT PATH; FOR EXAMPLE, EVALUATING LOW-FIELD MAGNETIC RESONANCE IMAGING, IMPROVING ACCESS TO COVID-19 TESTING IN INDIA THROUGH SYSTEM STRENGTHENING, EVALUATING A BLOW-FILL-SEAL ORAL VACCINE RECONSTITUTION DELIVERY SYSTEM, AND MARKET RESEARCH FOR NEWBORN SCREENING AND G6PD TESTING IN THE PRIVATE HEALTH SECTOR. MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM WORKS TO IMPROVE HEALTH EQUITY AND HEALTH OUTCOMES BY EVALUATING MARKETS, ASSESSING ROOT CAUSES OF LIMITED ACCESS TO HEALTH CARE PRODUCTS AND SERVICES, AND DESIGNING AND IMPLEMENTING MARKET-BASED INTERVENTIONS TO INCREASE ACCESS. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT/INTRODUCTION AND HEALTH SYSTEMS STRENGTHENING AND IS DONE IN CLOSE COLLABORATION WITH NATIONAL MINISTRIES OF HEALTH, GLOBAL AGENCIES, COMMERCIAL PARTNERS, AND PATH'S COUNTRY PROGRAMS.IN 2020, OUR WORK WAS FOCUSED PRIMARILY ON IMPROVING ACCESS TO MEDICAL OXYGEN AND RELATED RESPIRATORY CARE PRODUCTS FOR COVID-19 TREATMENT AS WELL AS MALARIA DRUGS AND DIAGNOSTICS.CENTER OF DIGITAL AND DATA EXCELLENCEPATH USES DIGITAL TECHNOLOGIES AND DATA-LED ACTION TO ADVANCE HEALTH EQUITY. IN 2020, PATH'S CENTER OF DIGITAL AND DATA EXCELLENCE (CODE) APPLIED ITS EXPERTISE TO ACCELERATE COUNTRY-LED DIGITAL HEALTH, DEEPEN THE USE OF DATA, AND SUPPORT THE GLOBAL COVID-19 RESPONSE. KEY ACCOMPLISHMENTS INCLUDED CO-AUTHORING WHO'S DIGITAL IMPLEMENTATION INVESTMENT GUIDE, WHICH OFFERS A SYSTEMIC PROCESS FOR COUNTRIES TO DEVELOP COSTED IMPLEMENTATION PLANS FOR DIGITAL HEALTH. DIGITAL SQUARE, A PATH-LED INITIATIVE, CONTINUED TO BRING DONORS AND PARTNERS TOGETHER TO IMPROVE HOW THE GLOBAL COMMUNITY DESIGNS, USES, AND PAYS FOR DIGITAL HEALTH TOOLS AND APPROACHES. DIGITAL SQUARE LED THE HEALTH DATA SCIENCE EXCHANGE, AN EXPLORATORY EFFORT TO UNDERSTAND HOW THE GREATER COORDINATION OF DATA SCIENCE TOOLS AND APPROACHES COULD IMPROVE HEALTH IMPACT. DIGITAL SQUARE ALSO BEGAN WORK ON MAP & MATCH, A LANDSCAPING ACTIVITY TO IDENTIFY EXISTING NATIONAL-LEVEL SOFTWARE TOOLS AND TECHNOLOGIES THAT CAN BE ADAPTED FOR COVID-19 RESPONSE. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $23,015,170 | ExpenseAmt |
| Grant | $5,154,512 | GrantAmt |
| Desc | ADVOCACY AND PUBLIC POLICYPATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, AT THE GLOBAL LEVEL WITH MULTILATERAL AGENCIES, AND IN COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH. IN 2020, PATH LED EFFORTS TO ENSURE SUPPORT AMONG POLICYMAKERS IN THE UNITED STATES, EUROPE, AND MULTILATERAL AGENCIES TO MAINTAIN AND STRENGTHEN WORK IN RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND PANDEMIC PREPAREDNESS AND RESPONSE. SUCCESSES INCLUDED PROTECTING KEY US GOVERNMENT FUNDING FOR PATH'S PRIORITY HEALTH AREAS, ENSURING US RE-INVESTMENT IN THE NEXT PHASE OF GAVI, AND HELPING DECISION-MAKERS CRAFT EMERGENCY FUNDING FOR THE GLOBAL RESPONSE TO COVID-19. WORKING WITH PARTNERS IN AFRICA, WE HELPED ADVANCE POLICIES TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN AND PROTECT ESSENTIAL HEALTH SERVICES AS THE COVID-19 PANDEMIC TOOK AN UNPRECEDENTED TOLL ON HEALTH SYSTEMS; FOR EXAMPLE, IN KENYA, OUR ADVOCACY RESULTED IN ESTABLISHMENT OF THE GLOBAL FINANCING FACILITY'S MULTI-STAKEHOLDER COUNTRY PLATFORM, WHICH GIVES CIVIL SOCIETY A VOICE IN GOVERNMENT FUNDING OF MATERNAL AND CHILD HEALTH PROGRAMS. IN SOUTH AFRICA, WE SUPPORTED THE COUNTRY'S HEALTH REGULATORY AGENCY AS IT STREAMLINED AND DISSEMINATED INFORMATION ABOUT THE APPROVAL PIPELINE FOR COVID-19 TOOLS AND TREATMENTS. IN UGANDA, WE SUCCESSFULLY ADVOCATED FOR INCREASED FUNDING FOR PRIMARY HEALTH CARE AND SUPPORTED THE NATIONAL IMMUNIZATION PROGRAM IN DEVELOPING A PLAN TO ROLL OUT COVID-19 VACCINATION AND CATCH UP ON MISSED IMMUNIZATIONS DURING THE PANDEMIC. AND IN THE DRC, WE SUCCESSFULLY ADVOCATED FOR FULL DISBURSEMENT OF THE GOVERNMENT'S CO-FINANCING COMMITMENTS TO GAVI AS WELL AS ADDITIONAL FUNDS FOR IMMUNIZATION IN THREE PROVINCES.SPECIAL INITIATIVESPATH IS ENGAGED IN A VARIETY OF SPECIAL INITIATIVES THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THOSE OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. BY THE END OF 2020, WE HAD ACTIVE HEALTH IMPACT TEAMS IN SEVEN HEALTH AREAS. EACH HEALTH IMPACT TEAM HAS BEEN ONGOING FOR AT LEAST THREE YEARS, WORKING TO BUILD STRUCTURED COLLABORATION ACROSS PROGRAMS AND GEOGRAPHIES TO INCREASE PATH'S IMPACT. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $23,015,170 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $5,154,512 | TotalOtherProgSrvcGrantAmt |
| Total Program Service Expenses | $262,890,896 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Donor Rstr Or Quasi Endowments | Yes (1) | DonorRstrOrQuasiEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | Yes (1) | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With35 Ctrl Ent | 0 | BusinessRlnWith35CtrlEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (1) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| Info In Schedule O Part V | Yes (X) | InfoInScheduleOPartVInd |
| IRP Document | 221 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 714 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (1) | ForeignFinancialAccountInd |
| Foreign Country | BE | ForeignCountryCd |
| Foreign Country | CH | ForeignCountryCd |
| Foreign Country | ET | ForeignCountryCd |
| Foreign Country | GH | ForeignCountryCd |
| Foreign Country | IN | ForeignCountryCd |
| Foreign Country | KE | ForeignCountryCd |
| Foreign Country | MZ | ForeignCountryCd |
| Foreign Country | PE | ForeignCountryCd |
| Foreign Country | SG | ForeignCountryCd |
| Foreign Country | SZ | ForeignCountryCd |
| Foreign Country | TZ | ForeignCountryCd |
| Foreign Country | UG | ForeignCountryCd |
| Foreign Country | UK | ForeignCountryCd |
| Foreign Country | VM | ForeignCountryCd |
| Foreign Country | ZA | ForeignCountryCd |
| Foreign Country | CG | ForeignCountryCd |
| Foreign Country | MI | ForeignCountryCd |
| Foreign Country | BM | ForeignCountryCd |
| Foreign Country | SF | ForeignCountryCd |
| Foreign Country | UP | ForeignCountryCd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 15 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 15 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | AR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | KY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MS | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NM | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OK | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | RI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | SC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TN | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | UT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WI | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WV | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | KELLY PRIESTLEY CONTROLLER | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVE SUITE 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (32 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| DAVID KING | |||||||||
| CHAIR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| BETH GALETTI | |||||||||
| VICE CHAIR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| YEHONG ZHANG | |||||||||
| SECRETARY | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| BRUCE MCNAMER | |||||||||
| TREASURER | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| FELIX OLALE | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JO ADDY | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| IREENA VITTAL | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| DEANNA OPPENHEIMER | |||||||||
| DIRECTOR (BEGAN 6/2020) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOHN-ARNE ROTTINGEN | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| JOEL HOLSINGER | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| HELENA WAYTH | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| SANFORD MELZER | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ABAYOMI SULE | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| LISA ANDERSON | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| RACHEL SIBANDE | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| STEPHEN B DAVIS | |||||||||
| PRESIDENT AND CEO (RESIGNED 1/2020) | 39.00 | 1.00 | Yes (X) | $249,057 | $0 | $13,602 | |||
| NIKOLAJ JESTED GILBERT | |||||||||
| PRESIDENT AND CEO (FROM 1/2020) | 39.00 | 1.00 | Yes (X) | $256,555 | $315,385 | $44,054 | |||
| JERRY KUO | |||||||||
| CHIEF OF STRATEGIC FINANCE | 39.00 | 1.00 | Yes (X) | $252,897 | $0 | $58,226 | |||
| BRIAN N NEVILLE | |||||||||
| CHIEF OF ACCOUNTING | 39.00 | 1.00 | Yes (X) | $260,514 | $0 | $36,826 | |||
| PHILIPPE GUINOT | |||||||||
| CHIEF OF BUSINESS, FIN. & OPS. | 39.00 | 1.00 | Yes (X) | $0 | $258,031 | $22,877 | |||
| DAVID C KASLOW | |||||||||
| VP - ESSENTIAL MEDICNES | 39.00 | 1.00 | $427,937 | $0 | $69,391 | Yes (X) | |||
| JEFFREY D BERNSON | |||||||||
| VP - TECH, ANALYTICS, MRKT INNOV. | 40.00 | 0.00 | $322,741 | $0 | $57,193 | Yes (X) | |||
| DAVID W FLEMING | |||||||||
| VP - PUBLIC HEALTH | 40.00 | 0.00 | $364,555 | $0 | $44,832 | Yes (X) | |||
| ELAINE L GIBBONS | |||||||||
| VP - GLOBAL ENGAGEMENT | 39.00 | 1.00 | $291,278 | $0 | $76,724 | Yes (X) | |||
| MOLLI M BARNES | |||||||||
| CHIEF PEOPLE OFFICER | 40.00 | 0.00 | $278,509 | $0 | $52,067 | Yes (X) | |||
| ERICA JANE SESSLE | |||||||||
| CHIEF OF STAFF | 40.00 | 0.00 | $238,815 | $0 | $54,599 | Yes (X) | |||
| SABRINA L POWERS | |||||||||
| GENERAL COUNSEL | 40.00 | 0.00 | $232,450 | $0 | $37,202 | Yes (X) | |||
| TRAD M HATTON | |||||||||
| COUNTRY DIRECTOR | 40.00 | 0.00 | $376,676 | $0 | $54,537 | Yes (X) | |||
| JAMES B MCKENNA | |||||||||
| DEPUTY DIRECTOR | 40.00 | 0.00 | $321,745 | $0 | $84,937 | Yes (X) | |||
| ASHLEY J BIRKETT | |||||||||
| GLOBAL HEAD, MALARIA VACCINES | 40.00 | 0.00 | $346,772 | $0 | $56,185 | Yes (X) | |||
| BRUCE LAMONT INNIS | |||||||||
| GLOBAL HEAD, RESPIRATORY INFECTIONS | 40.00 | 0.00 | $357,737 | $0 | $32,603 | Yes (X) | |||
| JOHN O KONZ | |||||||||
| GLOBAL HEAD, FINANCIAL MANAGEMENT | 40.00 | 0.00 | $346,902 | $0 | $67,132 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $4,925,140 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $573,416 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $862,987 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 373 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/ForeignAddress/AddressLine1Txt | CityContractorAddress/ForeignAddress/CityNm | CountryContractorAddress/ForeignAddress/CountryCd | Foreign PostalContractorAddress/ForeignAddress/ForeignPostalCd | ServicesServicesDesc | CompensationCompensationAmt | Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd |
|---|---|---|---|---|---|---|---|---|---|
| RANDSTAD INDIA PVT LTD | |||||||||
| SUIT NO 001 002 COPIA | NEW DELHI | IN | 110025 | STAFFING SERVICES | $996,065 | ||||
| SAFEGUARD WORLD INT'L | |||||||||
| MOSS LANE EDWIN FODEN BUS CENTRE | SANDBACH | UK | CW113AE | GENERAL CONTRACTOR | $890,294 | ||||
| WMBE PAYROLLING DBA TARGETCW | |||||||||
| GENERAL CONTRACTOR | $736,559 | 9475 CHESAPEAKE DR | SAN DIEGO | CA | 92123 | ||||
| JAMES G DAVIS CONTRUCTION CORPORATION | |||||||||
| GENERAL CONTRACTOR | $622,327 | 12530 PARKLAND DRIVE | ROCKVILLE | MD | 20852 | ||||
| INSTRUMENT LLC | |||||||||
| CONSULTING | $488,228 | 3529 NORTH WILLIAMS AVENUE | PORTLAND | OR | 97227 | ||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 45 | CntrctRcvdGreaterThan100KCnt |
| Related Organizations | $4,386,562 | RelatedOrganizationsAmt |
| Government Grants | $98,650,801 | GovernmentGrantsAmt |
| All Other Contributions | $184,417,020 | AllOtherContributionsAmt |
| Noncash Contributions | $761,052 | NoncashContributionsAmt |
| Total Contributions | $287,454,383 | TotalContributionsAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $12,207,084 | TotalRevenueColumnAmt |
| Exclusion | $12,207,084 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $57,083,069 | SecuritiesAmt |
| Other | $21,954 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $56,797,395 | SecuritiesAmt |
| Other | $12,461 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $285,674 | SecuritiesAmt |
| Other | $9,493 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $295,167 | TotalRevenueColumnAmt |
| Exclusion | $295,167 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| REIMBURSEMENTS | 900099 | $705,455 | $705,455 |
| OTHER | 900099 | $324,657 | $324,657 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $1,030,112 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $300,986,746 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $0 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $13,532,363 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $19,808,249 | TotalAmt |
| Program Services | $19,808,249 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $48,186,578 | TotalAmt |
| Program Services | $48,186,578 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,696,147 | TotalAmt |
| Program Services | $443,030 | ProgramServicesAmt |
| Management And General | $3,230,480 | ManagementAndGeneralAmt |
| Fundraising | $22,637 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $95,455,775 | TotalAmt |
| Program Services | $89,233,434 | ProgramServicesAmt |
| Management And General | $4,839,226 | ManagementAndGeneralAmt |
| Fundraising | $1,383,115 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $9,902,096 | TotalAmt |
| Program Services | $6,999,543 | ProgramServicesAmt |
| Management And General | $2,788,845 | ManagementAndGeneralAmt |
| Fundraising | $113,708 | FundraisingAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $16,637,172 | TotalAmt |
| Program Services | $13,244,535 | ProgramServicesAmt |
| Management And General | $3,259,730 | ManagementAndGeneralAmt |
| Fundraising | $132,907 | FundraisingAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,405,206 | TotalAmt |
| Program Services | $4,527,542 | ProgramServicesAmt |
| Management And General | $1,804,106 | ManagementAndGeneralAmt |
| Fundraising | $73,558 | FundraisingAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $805,000 | TotalAmt |
| Program Services | $428,419 | ProgramServicesAmt |
| Management And General | $376,581 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $478,838 | TotalAmt |
| Program Services | $186,280 | ProgramServicesAmt |
| Management And General | $292,558 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,845 | TotalAmt |
| Program Services | $1,845 | ProgramServicesAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $177,923 | TotalAmt |
| Management And General | $177,923 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $15,387,022 | TotalAmt |
| Program Services | $12,189,851 | ProgramServicesAmt |
| Management And General | $3,136,788 | ManagementAndGeneralAmt |
| Fundraising | $60,383 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $286,728 | TotalAmt |
| Program Services | $220,391 | ProgramServicesAmt |
| Management And General | $3,897 | ManagementAndGeneralAmt |
| Fundraising | $62,440 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,780,893 | TotalAmt |
| Program Services | $6,665,971 | ProgramServicesAmt |
| Management And General | $1,027,428 | ManagementAndGeneralAmt |
| Fundraising | $87,494 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,392,563 | TotalAmt |
| Program Services | $390,928 | ProgramServicesAmt |
| Management And General | $981,124 | ManagementAndGeneralAmt |
| Fundraising | $20,511 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $337,136 | TotalAmt |
| Program Services | $337,136 | ProgramServicesAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $12,679,852 | TotalAmt |
| Program Services | $272,765 | ProgramServicesAmt |
| Management And General | $12,407,087 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,889,458 | TotalAmt |
| Program Services | $7,460,553 | ProgramServicesAmt |
| Management And General | $423,813 | ManagementAndGeneralAmt |
| Fundraising | $5,092 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,292,304 | TotalAmt |
| Program Services | $5,113,342 | ProgramServicesAmt |
| Management And General | $174,332 | ManagementAndGeneralAmt |
| Fundraising | $4,630 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,904 | TotalAmt |
| Program Services | $154 | ProgramServicesAmt |
| Management And General | $1,750 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $3,101,076 | TotalAmt |
| Program Services | $12,403 | ProgramServicesAmt |
| Management And General | $3,088,673 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $849,014 | TotalAmt |
| Program Services | $210,678 | ProgramServicesAmt |
| Management And General | $638,336 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| SUBCONTRACTORS | $26,935,850 | $26,932,945 | $2,905 | |
| EQUIP RENT & MAINT | $6,595,821 | $5,287,573 | $1,303,962 | $4,286 |
| DIRECT AID TO BENEFICIA | $1,393,030 | $1,393,030 | ||
| FACILITIES ALLOC | $0 | $13,189,972 | -$13,402,840 | $212,868 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,582,003 | TotalAmt |
| Program Services | $153,749 | ProgramServicesAmt |
| Management And General | $1,201,997 | ManagementAndGeneralAmt |
| Fundraising | $226,257 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $293,059,483 | TotalAmt |
| Program Services | $262,890,896 | ProgramServicesAmt |
| Management And General | $27,758,701 | ManagementAndGeneralAmt |
| Fundraising | $2,409,886 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $8,845,877 | BOYAmt |
| EOY | $7,194,550 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $17,517,988 | BOYAmt |
| EOY | $9,719,000 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $44,215,907 | BOYAmt |
| EOY | $39,742,632 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $16,731,594 | BOYAmt |
| EOY | $258,036 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,170,218 | BOYAmt |
| EOY | $7,008,112 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $38,112,788 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $29,699,485 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,991,630 | BOYAmt |
| EOY | $8,413,303 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $138,590,941 | BOYAmt |
| EOY | $211,220,570 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $243,064,155 | BOYAmt |
| EOY | $283,556,203 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $204,045,574 | BOYAmt |
| EOY | $234,982,056 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $204,045,574 | BOYAmt |
| EOY | $234,982,056 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows FASB117 | Yes (X) | OrganizationFollowsFASB117Ind |
No Donor Restriction Net Assets NoDonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $20,518,990 | BOYAmt |
| EOY | $21,554,594 | EOYAmt |
Donor Restriction Net Assets DonorRestrictionNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $18,499,591 | BOYAmt |
| EOY | $27,019,553 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $39,018,581 | BOYAmt |
| EOY | $48,574,147 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $243,064,155 | BOYAmt |
| EOY | $283,556,203 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $7,927,263 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | $1,628,303 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $298,315,988 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $347,844,394 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $305,316,107 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $286,808,545 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $287,454,383 | CurrentTaxYearAmt |
| Total | $1,525,739,417 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $298,315,988 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $347,844,394 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $305,316,107 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $286,808,545 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $287,454,383 | CurrentTaxYearAmt |
| Total | $1,525,739,417 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $686,241,805 | SubstantialContributorsTotAmt |
| Public Support Total170 | $839,497,612 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,797,794 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,050,888 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,963,587 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $6,310,221 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $12,207,084 | CurrentTaxYearAmt |
| Total | $25,329,574 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $4,668,393 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $5,225,302 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $980,560 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $836,870 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,030,112 | CurrentTaxYearAmt |
| Total | $12,741,237 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $1,563,810,228 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $74,952 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.53680 | PublicSupportCY170Pct |
| Public Support PY170 | 0.56000 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Grassroots Lobbying TotalGrassrootsLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $405 | FilingOrganizationsTotalAmt |
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $134,788 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $135,193 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $292,924,290 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $293,059,483 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $294,096 | CurrentYearMinus3Amt |
| Current Year Minus2 | $224,944 | CurrentYearMinus2Amt |
| Current Year Minus1 | $163,912 | CurrentYearMinus1Amt |
| Current Year | $135,193 | CurrentYearAmt |
| Total | $818,145 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $127,336 | CurrentYearMinus3Amt |
| Current Year Minus2 | $7,856 | CurrentYearMinus2Amt |
| Current Year | $405 | CurrentYearAmt |
| Total | $135,597 | TotalAmt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $10,287,113 | BeginningYearBalanceAmt |
| Contributions | $2,745 | ContributionsAmt |
| Investment Earnings Or Losses | $1,095,576 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $454,711 | OtherExpendituresAmt |
| End Year Balance | $10,930,723 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,095,917 | BeginningYearBalanceAmt |
| Contributions | $2,100 | ContributionsAmt |
| Investment Earnings Or Losses | $1,691,617 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $502,521 | OtherExpendituresAmt |
| End Year Balance | $10,287,113 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $10,056,545 | BeginningYearBalanceAmt |
| Contributions | $1,240 | ContributionsAmt |
| Investment Earnings Or Losses | -$494,491 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $467,377 | OtherExpendituresAmt |
| End Year Balance | $9,095,917 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,339,249 | BeginningYearBalanceAmt |
| Contributions | $3,410 | ContributionsAmt |
| Investment Earnings Or Losses | $1,159,282 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $445,396 | OtherExpendituresAmt |
| End Year Balance | $10,056,545 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $8,897,224 | BeginningYearBalanceAmt |
| Contributions | $4,256 | ContributionsAmt |
| Investment Earnings Or Losses | $907,978 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $470,209 | OtherExpendituresAmt |
| End Year Balance | $9,339,249 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.36000 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 0.31000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.33000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $22,350,295 | OtherCostOrOtherBasisAmt |
| Depreciation | $15,697,322 | DepreciationAmt |
| Book Value | $6,652,973 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $10,509,124 | OtherCostOrOtherBasisAmt |
| Depreciation | $8,976,229 | DepreciationAmt |
| Book Value | $1,532,895 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $5,253,369 | OtherCostOrOtherBasisAmt |
| Depreciation | $5,025,934 | DepreciationAmt |
| Book Value | $227,435 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $8,413,303 | TotalBookValueLandBuildingsAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART V, LINE 4: | FormAndLineReferenceDesc |
| Explanation | PATH UTILIZES THE INVESTED INTREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (59 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $3,972,740 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $223,997 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $71,241 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $282,879 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | OTHER | $18,974 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $17,083 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | FUNDRAISING | FUNDRAISING | $88,125 |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | GRANTMAKING | $101,723 | |
| EAST ASIA AND THE PACIFIC | 5 | 110 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $1,168,919 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $6,333,906 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $298,774 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $253,294 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $62,526 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | OTHER | $40,996 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | FUNDRAISING | FUNDRAISING | $2,700 |
| EAST ASIA AND THE PACIFIC | 0 | 0 | GRANTMAKING | $10,343,468 | |
| EUROPE | 1 | 4 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $1,574,825 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $3,336,671 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $7,675,989 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $1,469,697 |
| EUROPE | 0 | 0 | PROGRAM SERVICES | OTHER | $48,919 |
| EUROPE | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $4,900 |
| EUROPE | 0 | 0 | GRANTMAKING | $23,791,380 | |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $3,238 |
| NORTH AMERICA | 0 | 0 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $74,544 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $188,511 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $1,164,008 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $8,008 |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | OTHER | $15,896 |
| NORTH AMERICA | 0 | 0 | FUNDRAISING | FUNDRAISING | $4,595 |
| NORTH AMERICA | 0 | 0 | GRANTMAKING | $383,489 | |
| RUSSIA AND NEIGHBORING STATES | 1 | 25 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $457,221 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $3,283,227 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $1,590 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $3,950 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | PROGRAM SERVICES | OTHER | $12 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $1,150 |
| RUSSIA AND NEIGHBORING STATES | 0 | 0 | GRANTMAKING | $1,556,551 | |
| SOUTH AMERICA | 1 | 3 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $46,002 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $274,890 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $7,574 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $60,715 |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | OTHER | $1,340 |
| SOUTH AMERICA | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $339 |
| SOUTH AMERICA | 0 | 0 | GRANTMAKING | $219,648 | |
| SOUTH ASIA | 6 | 133 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $2,234,260 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $4,834,839 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $1,496,048 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $435,904 |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | OTHER | $4,000 |
| SOUTH ASIA | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $51,747 |
| SOUTH ASIA | 0 | 0 | GRANTMAKING | $2,491,733 | |
| SUB-SAHARAN AFRICA | 43 | 621 | MANAGEMENT & GENERAL | MANAGEMENT & GENERAL | $7,301,830 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | GLOBAL HEALTH PROGRAM | $40,342,367 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | ESSENTIAL MEDICINE | $2,110,189 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | TECHNOLOGY, ANALYTICS AND MARKET INNOVATION | $2,250,189 |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | OTHER | $2,228,030 |
| SUB-SAHARAN AFRICA | 0 | 0 | BID & PROPOSAL | BID & PROPOSAL | $206,210 |
| SUB-SAHARAN AFRICA | 0 | 0 | GRANTMAKING | $9,298,586 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 57 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 896 | ContinuationTotalEmployeeCnt |
| Total Office | 57 | TotalOfficeCnt |
| Total Employee | 896 | TotalEmployeeCnt |
| Subtotal Spent | $4,776,762 | SubtotalSpentAmt |
| Continuation Spent | $139,449,394 | ContinuationSpentAmt |
| Total Spent | $144,226,156 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (180 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt |
|---|---|---|---|
| CENTRAL AMERICA AND THE CARIBBEAN | GLOBAL HEALTH PROGRAMS | $26,270 | CHECK/WIRE |
| CENTRAL AMERICA AND THE CARIBBEAN | GLOBAL HEALTH PROGRAMS | $45,720 | CHECK/WIRE |
| CENTRAL AMERICA AND THE CARIBBEAN | GLOBAL HEALTH PROGRAMS | $29,733 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $40,314 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $27,468 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $37,301 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $1,101,162 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $41,367 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $88,615 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $103,203 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $21,619 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $236,201 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $36,707 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $150,857 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $7,196 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $17,892 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $248,606 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $40,822 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $40,286 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $14,241 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $167,362 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $89,721 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $122,878 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $74,096 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $51,839 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $81,635 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $122,963 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $6,022,820 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $17,200 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $133,107 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $90,043 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $572,600 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $175,178 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $247,758 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $12,162 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $29,370 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | ESSENTIAL MEDICINE | $20,000 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $25,962 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | GLOBAL HEALTH PROGRAMS | $28,454 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $732,113 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $179,882 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $446,581 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $286,668 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $9,377 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $1,921,597 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $36,965 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $29,264 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $891,713 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $6,572,907 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $14,025 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $257,454 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $21,720 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $20,018 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $235,172 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $834,665 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $16,465 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $108,000 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $5,475 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $923,552 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $1,038,048 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $85,046 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $52,330 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $15,820 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $200,378 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $375,000 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $3,748,324 | CHECK/WIRE |
| EUROPE | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $23,132 | CHECK/WIRE |
| EUROPE | GLOBAL HEALTH PROGRAMS | $93,845 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE | $80,877 | CHECK/WIRE |
| EUROPE | ESSENTIAL MEDICINE, GLOBAL HEALTH PROGRAMS, TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS, AND OTHER | $4,534,968 | CHECK/WIRE |
| NORTH AMERICA | ESSENTIAL MEDICINE | $123,207 | CHECK/WIRE |
| NORTH AMERICA | GLOBAL HEALTH PROGRAMS | $25,000 | CHECK/WIRE |
| NORTH AMERICA | ESSENTIAL MEDICINE | $88,141 | CHECK/WIRE |
| NORTH AMERICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $147,141 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $24,863 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $44,978 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $13,118 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $7,300 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $67,764 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $18,856 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $61,591 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $14,589 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $75,073 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $17,646 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $430,980 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $18,758 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $22,231 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $65,868 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $15,353 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $30,681 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $32,256 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $33,427 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $114,951 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $149,600 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $58,055 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $72,813 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $9,762 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $104,693 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $23,730 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | GLOBAL HEALTH PROGRAMS | $24,210 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $108,625 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $10,816 | CHECK/WIRE |
| SOUTH AMERICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $16,445 | CHECK/WIRE |
| SOUTH AMERICA | GLOBAL HEALTH PROGRAMS | $83,762 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $175,937 | CHECK/WIRE |
| SOUTH ASIA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $7,801 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $285,788 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $55,019 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $87,424 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $38,652 | CHECK/WIRE |
| SOUTH ASIA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $24,470 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $296,153 | CHECK/WIRE |
| SOUTH ASIA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $137,360 | CHECK/WIRE |
| SOUTH ASIA | GLOBAL HEALTH PROGRAMS | $165,311 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $79,111 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $989,230 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $84,312 | CHECK/WIRE |
| SOUTH ASIA | ESSENTIAL MEDICINE | $65,165 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $13,911 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $124,740 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $104,229 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $5,046 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $145,235 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $46,437 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $26,070 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $1,616,490 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $21,305 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $6,582 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $21,615 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $1,009,409 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $820,924 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $139,523 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $437,058 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $33,819 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $37,762 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $98,022 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $26,585 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $13,210 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $25,791 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $226,644 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $12,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $314,600 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $54,880 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $12,911 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $6,720 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $14,480 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $125,404 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $208,292 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $39,725 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $217,405 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $184,370 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $6,883 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $134,626 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS AND OTHER | $47,900 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $57,658 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $69,703 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $439,709 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $8,659 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $18,450 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $50,069 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $6,286 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $6,271 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $5,350 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $450,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $8,343 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $83,928 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $45,130 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $8,795 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $6,134 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $5,787 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $67,892 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $20,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | $211,644 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $7,344 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $807,930 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | ESSENTIAL MEDICINE | $426,057 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $58,129 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $7,558 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $8,775 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | GLOBAL HEALTH PROGRAMS | $19,052 | CHECK/WIRE |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 139 | Total501c3OrgCnt |
| Total Other Org | 41 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (1) | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 2: | PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. |
| PART III ACCOUNTING METHOD: |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (69 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|
| ADARA DEVELOPMENT (USA) | ||||||||
| 300 ADMIRAL WY SUITE 106 | EDMONDS | WA | 98020 | 980634789 | 501(C)(3) | $14,499 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| BAGAMIAN SCIENTIFIC CONSULTING | ||||||||
| 222 NW 3RD AVE | GAINESVILLE | FL | 32601 | 821347380 | OTHER | $24,350 | ESSENTIAL MEDICINE | |
| BEHAVIORAL IDEAS LAB INC (DBA IDEAS42) | ||||||||
| 80 BROAD STREET 30TH FLOOR | NEW YORK | NY | 10004 | 271678009 | 501(C)(3) | $85,721 | GLOBAL HEALTH PROGRAMS | |
| BIOIVT LLC | ||||||||
| 123 FROST ST STE 115 | WESTBURY | NY | 11590 | 271867431 | OTHER | $38,950 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| CENTERS FOR DISEASE CONTROL AND PREVENTION | ||||||||
| 1600 CLIFTON ROAD | ATLANTA | GA | 30333 | 586051157 | GOV | $71,016 | ESSENTIAL MEDICINE | |
| CHILDREN'S HOSPITAL BOSTON | ||||||||
| RESEARCH FINANCE PO BOX 414413 | BOSTON | MA | 022414413 | 042774441 | 501(C)(3) | $599,612 | ESSENTIAL MEDICINE | |
| CINCINNATI CHILDREN'S HOSPITAL | ||||||||
| MEDICAL CENTER 3333 BURNET AVE ML | CINCINNATI | OH | 452293039 | 310833936 | 501(C)(3) | $407,166 | ESSENTIAL MEDICINE | 6014 |
| CLINTON HEALTH ACCESS INITIATIVE | ||||||||
| 383 DORCHESTER AVE SUITE 400 | BOSTON | MA | 02127 | 271414646 | 501(C)(3) | $2,624,024 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| COOPERSMITH | ||||||||
| 4206 RIVER RD NW | WASHINGTON | DC | 20016 | 472387850 | OTHER | $116,315 | GLOBAL HEALTH PROGRAMS | |
| DIMAGI INC | ||||||||
| 585 MASSACHUSETTS AVE SUITE 4 | CAMBRIDGE | MA | 02139 | 830343298 | 501(C)(3) | $40,477 | GLOBAL HEALTH PROGRAMS | |
| FINA BIOSOLUTIONS LLC | ||||||||
| 9430 KEY WEST AVE SUITE 200 | ROCKVILLE | MD | 20850 | 205448275 | OTHER | $217,000 | ESSENTIAL MEDICINE | |
| FOOD AND DRUG ADMINISTRATION | ||||||||
| 5600 FISHERS LANEHFA-140 ROOM 11-40 | ROCKVILLE | MD | 20857 | 530196965 | GOV | $103,750 | ESSENTIAL MEDICINE | 11-40 |
| FRED HUTCHINSON CANCER RESEARCH CENTER | ||||||||
| 1100 FAIRVIEW AVE N PO BOX 19024 | SEATTLE | WA | 981091024 | 237156071 | 501(C)(3) | $26,177 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| G&L SCIENTIFIC INC | ||||||||
| 25 INDEPENDENCE BLVD SUITE 404 | WARREN | NJ | 07059 | 811114075 | OTHER | $8,185 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| GLOBAL CONNECT DEVELOPMENT GROUP LLC | ||||||||
| 480 BEACH ST | BOSTON | MA | 02131 | 823433604 | OTHER | $71,525 | GLOBAL HEALTH PROGRAMS | |
| GLOBAL HEALTH CORPS | ||||||||
| 318 WEST 39TH STREET ROOM 9L | NEW YORK | NY | 10018 | 800512336 | 501(C)(3) | $6,045 | GLOBAL HEALTH PROGRAMS | |
| GLOBAL HEALTH STRATEGIES LLC | ||||||||
| 27 WEST 24TH STREET SUITE 900 | NEW YORK | NY | 10010 | 272494697 | 501(C)(3) | $280,713 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| GUARALDI SYSTEMS LLC | ||||||||
| 97 ALGER BROOK RD | SOUTH STAFFORD | VT | 05070 | 851148274 | OTHER | $117,040 | GLOBAL HEALTH PROGRAMS | |
| HARVARD SCHOOL OF PUBLIC HEALTH | ||||||||
| 677 HUNTINGTON AVENUE | BOSTON | MA | 02215 | 042103580 | 501(C)(3) | $691,653 | ESSENTIAL MEDICINE | |
| HARVARD UNIVERSITY | ||||||||
| 1033 MASSACHUSETTS AVE 2ND FLOOR | CAMBRIDGE | MA | 02115 | 042103580 | 501(C)(3) | $165,466 | ESSENTIAL MEDICINE AND GLOBAL HEALTH PROGRAMS | |
| HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC | ||||||||
| 6720-A ROCKLEDGE DRIVE STE 100 | BETHESDA | MD | 20817 | 521317896 | 501(C)(3) | $69,910 | ESSENTIAL MEDICINE | |
| HISP US LLC | ||||||||
| 31 ANCONA AVE | OCEAN PARK | ME | 04063 | 850894858 | OTHER | $121,924 | GLOBAL HEALTH PROGRAMS | |
| HJF MEDICAL RESEARCH INTERNATIONAL INC | ||||||||
| 6720A ROCKLEDGE DRIVE SUITE 100 | BETHESDA | MD | 20817 | 522322791 | 501(C)(3) | $815,715 | ESSENTIAL MEDICINE | |
| ICF MACRO INC | ||||||||
| 9300 LEE HIGHWAY | FAIRFAX | VA | 22031 | 223661438 | OTHER | $1,432,031 | GLOBAL HEALTH PROGRAMS | |
| INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE ( IFPRI ) | ||||||||
| 1201 EYE STREET NW | WASHINGTON | DC | 20005 | 521041632 | 501(C)(3) | $118,841 | GLOBAL HEALTH PROGRAMS | |
| INTRAHEALTH INTERNATIONAL INC | ||||||||
| 6340 QUADRANGLE DRIVE SUITE 200 | CHAPEL HILL | NC | 27517 | 550825466 | 501(C)(3) | $490,617 | GLOBAL HEALTH PROGRAMS | |
| IPAS | ||||||||
| 300 MARKET ST 200 | CHAPEL HILL | NC | 27516 | 561071085 | 501(C)(3) | $20,000 | GLOBAL HEALTH PROGRAMS | |
| JHPIEGO | ||||||||
| 1615 THAMES STREET SUITE 200 | BALTIMORE | MD | 212313447 | 237424444 | 501(C)(3) | $59,904 | GLOBAL HEALTH PROGRAMS | |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| BLOOMBERG SCHL OF PUB HLTH 615 N | BALTIMORE | MD | 21205 | 520595110 | 501(C)(3) | $47,858 | GLOBAL HEALTH PROGRAMS | WOLFE STREET |
| JSI RESEARCH AND TRAINING INSTITUTE INC | ||||||||
| 1616 NORTH FORT MYER DR 16TH FLOOR | ARLINGTON | VA | 222093100 | 042679824 | 501(C)(3) | $1,101,159 | GLOBAL HEALTH PROGRAMS | |
| LINKSBRIDGE SPC | ||||||||
| 101 TAYLOR AVE N 105 | SEATTLE | WA | 98109 | 263067893 | OTHER | $57,926 | ESSENTIAL MEDICINE | |
| MAGEE-WOMENS RESEARCH INSTITUTE AND FOUNDATION | ||||||||
| 3339 WARD ST | PITTSBURGH | PA | 15213 | 251462312 | 501(C)(3) | $13,300 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| MANAGEMENT SCIENCES FOR HEALTH INC | ||||||||
| 200 RIVERS EDGE DRIVE SUITE 320 | MEDFORD | MA | 02155 | 042482188 | 501(C)(3) | $60,827 | GLOBAL HEALTH PROGRAMS | |
| MASS DESIGN GROUP LTD | ||||||||
| 334 BOYLSTON ST STE 400 | BOSTON | MA | 02116 | 611659704 | 501(C)(3) | $50,000 | GLOBAL HEALTH PROGRAMS | |
| MASSACHUSETTS GENERAL HOSPITAL | ||||||||
| DEPT OF EMERGENCY MEDICINE ZERO | BOSTON | MA | 02114 | 041564655 | 501(C)(3) | $236,406 | ESSENTIAL MEDICINE | EMERSON PL 104 |
| MASSACHUSETTS INSTITUTE OF TECHNOLOGY | ||||||||
| 77 MASSACHUSETTS AVENUE | CAMBRIDGE | MA | 02139 | 042103594 | 501(C)(3) | $20,443 | ESSENTIAL MEDICINE | |
| MEDIC MOBILE INC | ||||||||
| 3254 19TH STREET FLOOR 2 | SAN FRANCISCO | CA | 94110 | 275104203 | 501(C)(3) | $31,647 | GLOBAL HEALTH PROGRAMS | |
| MICHIGAN STATE UNIVERSITY | ||||||||
| 3900 COLLINS RD SUITE 1044 | LANSING | MI | 48910 | 386005984 | 501(C)(3) | $132,399 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| MICRON BIOMEDICAL INC | ||||||||
| 311 FERST DR NW SUITE L1309 | ATLANTA | GA | 30332 | 471692844 | OTHER | $113,633 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| NATIONAL FOUNDATION FOR THE CDC | ||||||||
| 55 PARK PLACE SUITE 400 | ATLANTA | GA | 30303 | 582106707 | 501(C)(3) | $185,563 | ESSENTIAL MEDICINE | |
| NAT'L INST OF ALLERGY & INFECTIOUS DISEASES | ||||||||
| 6610 ROCKLEDGE DR ROOM 2800 | BETHESDA | MD | 208926606 | 520858115 | GOV | $480,134 | ESSENTIAL MEDICINE | |
| NICHOLAS INSTITUTE FOR ENVIRONMENTAL POLICY SOLUTIONS AT DUKE UNIVERSITY | ||||||||
| 2117 CAMPUS DRIVE PO BOX 90335 | DURHAM | NC | 27708 | 560532129 | 501(C)(3) | $5,418 | GLOBAL HEALTH PROGRAMS | |
| ONA SYSTEMS INC | ||||||||
| 126 E 12TH ST SUITE 4A | NEW YORK | NY | 100035320 | 383940780 | OTHER | $134,412 | GLOBAL HEALTH PROGRAMS | |
| OPENMRS INC | ||||||||
| 10425 COMMERCE DR STE 110 | CARMEL | IN | 460327643 | 455316647 | 501(C)(3) | $36,768 | GLOBAL HEALTH PROGRAMS | |
| PARSYL INC | ||||||||
| 3963 WALNUT STREET STE 200 | DENVER | CO | 80205 | 814027966 | OTHER | $8,500 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| PATHFINDER INTERNATIONAL | ||||||||
| 9 GALEN STREET SUITE 217 | WATERTOWN | MA | 02472 | 530235320 | 501(C)(3) | $116,459 | GLOBAL HEALTH PROGRAMS | |
| PHARMARON CPC INC | ||||||||
| 800 W BALTIMORE STREET 5TH FLOOR | BALTIMORE | MD | 21201 | 208419781 | OTHER | $1,321,003 | ESSENTIAL MEDICINE | |
| POPULATION COUNCIL | ||||||||
| ONE DAG HAMMERKJOLD PLAZA | NEW YORK | NY | 10017 | 131687001 | 501(C)(3) | $127,341 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| POPULATION SERVICES INTERNATIONAL INC | ||||||||
| 1120 19TH ST NW STE 600 | WASHINGTON | DC | 20036 | 560942853 | 501(C)(3) | $268,142 | GLOBAL HEALTH PROGRAMS AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| REGENSTRIEF INSTITUTE INC | ||||||||
| 1101 W 10TH ST | INDIANAPOLIS | IN | 46202 | 300007730 | 501(C)(3) | $57,528 | GLOBAL HEALTH PROGRAMS | |
| ROSTROPOVICH-VISHNEVSKAYA FOUNDATION | ||||||||
| 1776 K STREET NW SUITE 700 | WASHINGTON | DC | 20006 | 521752473 | 501(C)(3) | $58,486 | ESSENTIAL MEDICINE | |
| SOLAR ELECTRIC LIGHT FUND | ||||||||
| 1612 K STREET NW SUITE 300 | WASHINGTON | DC | 20006 | 521701564 | 501(C)(3) | $39,729 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | |
| SYSTEMONE LLC | ||||||||
| 5 BRIDGE STREET | SHELBURNE FALLS | MA | 01370 | 461066795 | OTHER | $86,525 | GLOBAL HEALTH PROGRAMS | |
| TECHCHANGE INC | ||||||||
| 2001 13TH ST NW 2ND FLOOR | WASHINGTON | DC | 20009 | 273358772 | OTHER | $321,300 | GLOBAL HEALTH PROGRAMS | |
| THE ALBERT B SABIN VACCINE INSTITUTE INC | ||||||||
| 2175 K STREET NW SUITE 400 | WASHINGTON | DC | 20037 | 061389829 | 501(C)(3) | $50,000 | ESSENTIAL MEDICINE | |
| THE NATURE CONSERVANCY | ||||||||
| 4245 FAIRFAX DRIVE | ARLINGTON | VA | 22203 | 530242652 | 501(C)(3) | $18,500 | GLOBAL HEALTH PROGRAMS | |
| THE REGENTS OF THE UNIVERSITY OF CALIFORNIA SAN FRANCISCO | ||||||||
| UCSF OFFICE OF SPONSORED RES 3333 | SAN FRANCISCO | CA | 94118 | 946036493 | 501(C)(3) | $182,685 | GLOBAL HEALTH PROGRAMS AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | CALIFORNIA ST STE 315 |
| THE STATE UNIVERSITY OF NEW YORK | ||||||||
| 35 STATE STREET | ALBANY | NY | 122072826 | 141368361 | 501(C)(3) | $155,082 | ESSENTIAL MEDICINE | |
| TULANE UNIVERSITY | ||||||||
| 6823 ST CHARLES AVE | NEW ORLEANS | LA | 70112 | 720423889 | 501(C)(3) | $459,580 | ESSENTIAL MEDICINE AND GLOBAL HEALTH PROGRAMS | |
| UNIVERSITY OF ALABAMA | ||||||||
| GRANTS CONTRACTS ACCOUNTING AB 990 | BIRMINGHAM | AL | 352940109 | 636005396 | GOV | $85,011 | ESSENTIAL MEDICINE | |
| UNIVERSITY OF MASSACHUSETTS | ||||||||
| MEDICAL SCHOOL 55 LAKE AVENUE NORTH | WORCESTER | MA | 01655 | 043167352 | GOV | $31,089 | TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | NORTH |
| UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | ||||||||
| CENTER FOR INFECTIOUS DISEASES | CHAPEL HILL | NC | 275993368 | 566001393 | 501(C)(3) | $137,024 | GLOBAL HEALTH PROGRAMS | |
| UNIVERSITY OF WASHINGTON | ||||||||
| GRANT CONTRACT ACCOUNTING 12455 | CHICAGO | IL | 60693 | 916001537 | 501(C)(3) | $1,542,732 | ESSENTIAL MEDICINE, GLOBAL HEALTH PROGRAMS, AND TECHNOLOGY ANALYTICS AND MARKET INNOVATIONS | COLLECTIONS DRIVE |
| VILLAGEREACH | ||||||||
| 2900 EASTLAKE AVE E SUITE 230 | SEATTLE | WA | 981023012 | 912088484 | 501(C)(3) | $256,118 | GLOBAL HEALTH PROGRAMS | |
| VITAL STRATEGIES INC | ||||||||
| 100 BROADWAY 4TH FLOOR | NEW YORK | NY | 10005 | 223419667 | 501(C)(3) | $9,488 | GLOBAL HEALTH PROGRAMS | |
| VITAL WAVE INC | ||||||||
| 555 BRYANT STREET 226 | PALO ALTO | CA | 94301 | 203208079 | OTHER | $284,978 | GLOBAL HEALTH PROGRAMS | |
| WALTER REED ARMY INSTITUTE OF RESEARCH | ||||||||
| US TREASURY 503 ROBERT GRANT AVE | SILVER SPRING | MD | 20910 | 520664528 | GOV | $2,487,368 | ESSENTIAL MEDICINE | |
| WASHINGTON STATE UNIVERSITY | ||||||||
| 901 5TH AVE SUITE 2900 | SEATTLE | WA | 98164 | 916001108 | GOV | $104,777 | GLOBAL HEALTH PROGRAMS | |
| PATH VACCINE SOLUTIONS | ||||||||
| 2201 WESTLAKE AVE SUITE 200 | SEATTLE | WA | 98121 | 943384500 | 501(C)(3) | $46,272 | ESSENTIAL MEDICINE, GLOBAL HEALTH PROGRAMS, AND MANAGEMENT | |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 52 | Total501c3OrgCnt |
| Total Other Org | 17 | TotalOtherOrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Idemnification Gross Up Pmts | Yes (X) | IdemnificationGrossUpPmtsInd |
| Housing Allowance Or Residence | Yes (X) | HousingAllowanceOrResidenceInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (17 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NIKOLAJ JESTED GILBERT | ||||||||||||||
| PRESIDENT AND CEO (FROM 1/2020) | $183,894 | $292,691 | $0 | $0 | $72,661 | $22,694 | $9,000 | $23,249 | $11,176 | $629 | $276,731 | $339,263 | $0 | $0 |
| DAVID C KASLOW | ||||||||||||||
| VP - ESSENTIAL MEDICNES | $425,987 | $0 | $0 | $0 | $1,950 | $0 | $34,200 | $0 | $35,191 | $0 | $497,328 | $0 | $0 | $0 |
| TRAD M HATTON | ||||||||||||||
| COUNTRY DIRECTOR | $196,161 | $0 | $0 | $0 | $180,515 | $0 | $19,167 | $0 | $35,370 | $0 | $431,213 | $0 | $0 | $0 |
| JOHN O KONZ | ||||||||||||||
| GLOBAL HEAD, FINANCIAL MANAGEMENT | $346,062 | $0 | $0 | $0 | $840 | $0 | $34,200 | $0 | $32,932 | $0 | $414,034 | $0 | $0 | $0 |
| DAVID W FLEMING | ||||||||||||||
| VP - PUBLIC HEALTH | $362,605 | $0 | $0 | $0 | $1,950 | $0 | $34,200 | $0 | $10,632 | $0 | $409,387 | $0 | $0 | $0 |
| JAMES B MCKENNA | ||||||||||||||
| DEPUTY DIRECTOR | $271,132 | $0 | $0 | $0 | $50,613 | $0 | $26,023 | $0 | $58,914 | $0 | $406,682 | $0 | $0 | $0 |
| ASHLEY J BIRKETT | ||||||||||||||
| GLOBAL HEAD, MALARIA VACCINES | $345,577 | $0 | $0 | $0 | $1,195 | $0 | $27,138 | $0 | $29,047 | $0 | $402,957 | $0 | $0 | $0 |
| BRUCE LAMONT INNIS | ||||||||||||||
| GLOBAL HEAD, RESPIRATORY INFECTIONS | $356,827 | $0 | $0 | $0 | $910 | $0 | $32,603 | $0 | $0 | $0 | $390,340 | $0 | $0 | $0 |
| JEFFREY D BERNSON | ||||||||||||||
| VP - TECH, ANALYTICS, MRKT INNOV. | $322,366 | $0 | $0 | $0 | $375 | $0 | $32,680 | $0 | $24,513 | $0 | $379,934 | $0 | $0 | $0 |
| ELAINE L GIBBONS | ||||||||||||||
| VP - GLOBAL ENGAGEMENT | $289,328 | $0 | $0 | $0 | $1,950 | $0 | $33,296 | $0 | $43,428 | $0 | $368,002 | $0 | $0 | $0 |
| MOLLI M BARNES | ||||||||||||||
| CHIEF PEOPLE OFFICER | $278,509 | $0 | $0 | $0 | $0 | $0 | $29,341 | $0 | $22,726 | $0 | $330,576 | $0 | $0 | $0 |
| JERRY KUO | ||||||||||||||
| CHIEF OF STRATEGIC FINANCE | $251,067 | $0 | $0 | $0 | $1,830 | $0 | $30,616 | $0 | $27,610 | $0 | $311,123 | $0 | $0 | $0 |
| BRIAN N NEVILLE | ||||||||||||||
| CHIEF OF ACCOUNTING | $258,594 | $0 | $0 | $0 | $1,920 | $0 | $27,852 | $0 | $8,974 | $0 | $297,340 | $0 | $0 | $0 |
| ERICA JANE SESSLE | ||||||||||||||
| CHIEF OF STAFF | $236,865 | $0 | $0 | $0 | $1,950 | $0 | $28,554 | $0 | $26,045 | $0 | $293,414 | $0 | $0 | $0 |
| PHILIPPE GUINOT | ||||||||||||||
| CHIEF OF BUSINESS, FIN. & OPS. | $0 | $251,954 | $0 | $0 | $0 | $6,077 | $0 | $21,918 | $0 | $959 | $0 | $280,908 | $0 | $0 |
| SABRINA L POWERS | ||||||||||||||
| GENERAL COUNSEL | $232,120 | $0 | $0 | $0 | $330 | $0 | $27,838 | $0 | $9,364 | $0 | $269,652 | $0 | $0 | $0 |
| STEPHEN B DAVIS | ||||||||||||||
| PRESIDENT AND CEO (RESIGNED 1/2020) | $50,912 | $0 | $156,629 | $0 | $41,516 | $0 | $11,120 | $0 | $2,482 | $0 | $262,659 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 1A | HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT. |
| PART I, LINE 7 | BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 14 | ContributionCnt |
| Noncash Contributions Rpt F990 | $92,087 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
Other Non Cash Contri Table OtherNonCashContriTableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Desc | SOFTWARE/SUPP. | Desc |
| Contribution | 5 | ContributionCnt |
| Noncash Contributions Rpt F990 | $668,965 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | COST | MethodOfDeterminingRevenuesTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (9 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 1, DESCRIPTION OF ORGANIZATION MISSION: | PATH IS A GLOBAL ORGANIZATION THAT WORKS TO ACCELERATE HEALTH EQUITY BY BRINGING TOGETHER PUBLIC INSTITUTIONS, BUSINESSES, SOCIAL ENTERPRISES, AND INVESTORS TO SOLVE THE WORLD'S MOST PRESSING HEALTH CHALLENGES. WITH EXPERTISE IN SCIENCE, HEALTH, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES UP SOLUTIONS-INCLUDING VACCINES, DRUGS, DEVICES, DIAGNOSTICS, AND INNOVATIVE APPROACHES TO STRENGTHENING HEALTH SYSTEMS WORLDWIDE. SINCE 2011, PATH AND OUR PARTNERS AND SUPPORTERS HAVE IMPROVED HEALTH FOR MORE THAN 150 MILLION PEOPLE ON AVERAGE EACH YEAR. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | IN UKRAINE, PATH CONTINUED TO LEAD THE USAID-FUNDED SERVING LIFE PROJECT, WHICH REDUCES TB, HIV, AND HEPATITIS C VIRUS (HCV) TRANSMISSION IN THE PENAL SYSTEM AND COMMUNITIES ACROSS 12 REGIONS. RESPONDING TO COVID-19, WE OFFERED MULTIPLE OPTIONS FOR HIVST KIT DELIVERY AND ADVOCATED FOR VIRTUAL ART INITIATION AND MONITORING; WITHIN TWO MONTHS OF ENACTMENT OF A NEW POLICY, ALMOST 400 VIRTUAL CONSULTATIONS WERE HELD. IN ADDITION, WITH PATH'S TECHNICAL SUPPORT AND SUCCESSFUL ADVOCACY, THE MINISTRY OF JUSTICE PROCURED 60,000 HCV RAPID TESTS AND THE DRUGS REQUIRED TO TREAT NEARLY 500 PRISONERS WITH HCV. AS A PARTNER IN THE UNITAID-FUNDED ADHERENCE SUPPORT COALITION TO END TB PROJECT, PATH BEGAN A STUDY IN UKRAINE ON IMPLEMENTATION OF DIGITAL ADHERENCE TECHNOLOGIES (DATS) AND WORKED TO ESTABLISH A GLOBAL MARKET FOR DATS; FOR EXAMPLE, THE WISEPILL DIGITAL PILLBOX. BY THE END OF 2020, WISEPILL WAS THE FIRST-EVER DAT INCLUDED IN THE GLOBAL DRUG FACILITY CATALOGUE. PATH ALSO CONTINUED TO IMPLEMENT THE USAID-FUNDED SUPPORT TB CONTROL EFFORTS IN UKRAINE (STBCEU) PROJECT, WHICH FOCUSES ON PREVENTION, DETECTION, AND TREATMENT OF TB, DRUG-RESISTANT TB, AND TB/HIV. IN 2020, STBCEU RAPIDLY ADAPTED PROJECT ACTIVITIES TO A REMOTE MODEL. WE ALSO BEGAN SCALE-UP OF A SUCCESSFUL NEW APPROACH FOR TRANSPORTING DIAGNOSTIC SPECIMENS AND DELIVERING DRUGS TO TREAT TB AND HIV. WHEN USAID PROVIDED ADDITIONAL FUNDING FOR EMERGENCY RESPONSE TO COVID-19, PATH PROCURED DNA EXTRACTORS AND CONDUCTED ON-THE-JOB TRAINING TO DRAMATICALLY INCREASE THE NUMBER OF SAMPLES FOR COVID-19 (AND OTHER DISEASES) THAT COULD BE TESTED IN A DAY. THE NUMBER OF UNPROCESSED SAMPLES AT ONE LABORATORY WENT FROM 800 TO ZERO IN LESS THAN A MONTH AND REMAINED AT ZERO THROUGH THE END OF 2020. IN INDIA, PATH ENHANCED HIV SERVICE DELIVERY THROUGH AUTOMATION OF DATA AND DEVELOPMENT OF A MACHINE-LEARNING-ENABLED TOOL TO REDUCE LOSS OF PATIENTS FROM TREATMENT. TO IMPROVE TB SERVICES, WE PILOTED ARTIFICIAL INTELLIGENCE TO STREAMLINE CHEST X-RAY READINGS, ENABLING QUICKER DIAGNOSIS AND INITIATION ON TREATMENT. IN TAJIKISTAN, KAZAKHSTAN, AND UZBEKISTAN, PATH DEVELOPED DRUG-RESISTANT TB CASE MANAGEMENT GUIDELINES, SET UP A DIGITAL TB PREVENTION PLATFORM, PROVIDED TECHNICAL EXPERTISE ON LATENT TB INFECTION, AND MORE FOR THE USAID ELIMINATING TB IN CENTRAL ASIA PROJECT. IN TANZANIA, THE USAID-FUNDED INFECTIOUS DISEASE DETECTION AND SURVEILLANCE (IDDS) PROJECT SUPPORTED KEY FUNCTIONS AT THE CENTRAL TB REFERENCE LABORATORY, FACILITATED REPORTING FROM GENEXPERT TESTING SITES, AND ASSESSED THE TB DIAGNOSTIC NETWORK. IN VIETNAM, PATH CONTINUED TO PIONEER DIFFERENTIATED AND INTEGRATED SERVICE DELIVERY THROUGH THE USAID HEALTHY MARKETS PROJECT. IN 2020, HEALTHY MARKETS ADDED NEW MODES OF DELIVERY FOR PRE-EXPOSURE PROPHYLAXIS AND HIVST. THE PROJECT ALSO CREATED ONE-STOP SHOPS OFFERING PREVENTION, TESTING, AND TREATMENT FOR HIV AND SEXUALLY TRANSMITTED INFECTIONS; MENTAL HEALTH SCREENING AND REFERRALS; GENDER-AFFIRMING SERVICES; AND HEPATITIS B AND C SCREENING AND TREATMENT FOR PLHIV. THE PROJECT USED SOCIAL MEDIA, WEBSITES, AND TELEPHONE HOTLINES TO PROMOTE AND SUPPORT THESE SERVICES AND RAISE AWARENESS OF COVID-19. THESE ADAPTATIONS WERE CRITICAL TO NOT ONLY CONTINUING BUT ACTUALLY INCREASING SERVICES DURING THE PANDEMIC; FOR EXAMPLE, THE PROJECT'S ONLINE HIVST 3.0 ORDERING PLATFORM AND HOME DELIVERY RESULTED IN A 93 PERCENT INCREASE IN THE NUMBER OF HIVST KITS DISTRIBUTED TO KEY POPULATIONS. THROUGH THE IDDS PROJECT IN VIETNAM, PATH CONTINUED TO SUPPORT THE NATIONAL TUBERCULOSIS PROGRAM (NTP). IDDS ASSESSED PROGRESS ON THE "DOUBLE X" STRATEGY (CHEST X-RAY AND GENEXPERT TEST) AND PUT FORTH EVIDENCE-BASED RECOMMENDATIONS TO IMPROVE IMPLEMENTATION. THE BREATH FOR LIFE (B4L) PROJECT 2.0 IN VIETNAM IMPROVED AND SCALED UP THE B4L MODEL DEVELOPED IN PRIOR YEARS. B4L 2.0 INCREASED ACCURATE DIAGNOSIS OF PEDIATRIC TB, TREATMENT OF TB AND LATENT TB, AND TB PREVENTION. FOLLOWING A STOOL-BASED GENEXPERT TESTING PILOT, B4L 2.0 AND IDDS PAIRED UP TO SUPPORT THE NTP IN THE USE OF STOOL SAMPLES TO INCREASE TB DETECTION AMONG CHILDREN. IMPORTANTLY, THE VIETNAM NTP INCLUDED PEDIATRIC TB ACTIVITIES INFORMED BY B4L IN ITS STRATEGIC PLAN 2021-2025. IN ZAMBIA, PATH CONTINUED TO IMPLEMENT THE USAID-FUNDED ERADICATE TB PROJECT, WHICH TESTED NEARLY 150,000 PEOPLE AND DIAGNOSED APPROXIMATELY 21,000 WITH TB. OF THE NEARLY 9,000 BACTERIOLOGICALLY CONFIRMED INDIVIDUALS, 95 PERCENT WERE INITIATED ON TREATMENT. TO MITIGATE COVID-19, THE PROJECT CONDUCTED INFECTION PREVENTION AND CONTROL TRAININGS FOR MORE THAN 500 HEALTH CARE WORKERS, COMPLETED FOLLOW-UP FACILITY ASSESSMENTS, ACTIVATED THREE TESTING SITES, AND ORIENTED 500 COMMUNITY-BASED VOLUNTEERS. MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION (MNCHN) IS PART OF PATH'S COMPREHENSIVE, ONE HEALTH, PEOPLE- AND COMMUNITY-CENTERED PRIMARY HEALTH CARE MODEL, WHICH ADDRESSES BROADER DETERMINANTS OF HEALTH (E.G., SOCIAL, ECONOMIC, ENVIRONMENTAL). WE FOCUS ON INNOVATIVE, EVIDENCE-BASED TOOLS AND APPROACHES TO MEET PEOPLE'S NEEDS AND PREFERENCES ACROSS THEIR LIFETIME. TOGETHER WITH PARTNERS AROUND THE WORLD, WE DEVELOP, ADAPT, AND SCALE UP TECHNOLOGIES AND SYSTEMS TO REDUCE ILLNESS AND DEATH AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. IN 2020, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD); FOR INSTANCE, WITH PATH SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, AND MOZAMBIQUE CONTINUED TO INCORPORATE ECD SERVICES INTO BASIC HEALTH CARE. THIS PIONEERING WORK CENTERS AROUND BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE STRENGTHENING THE CAPACITY OF HEALTH SYSTEMS AND HEALTH SERVICE PROVIDERS. ALONG WITH WHO, UNICEF, THE WORLD BANK, AND OTHERS, PATH PROMOTED THE NURTURING CARE FOR ECD FRAMEWORK-A STRUCTURE FOR COUNTRIES TO ADOPT, ADAPT, AND SCALE UP ECD SERVICES. TO ENSURE THAT ALL INFANTS HAVE ACCESS TO HUMAN MILK, PATH FOCUSES ON BREASTFEEDING PROMOTION, INCLUDING PROVISION OF SAFE DONOR MILK THROUGH LOCAL HUMAN MILK BANKS. IN 2020, WE CONTINUED TO ADVOCATE FOR UPTAKE AND USE OF GLOBAL STANDARDS FOR STRENGTHENING HUMAN MILK BANKING. WE ALSO BEGAN CO-DEVELOPING A DIGITAL KIT TO OPTIMIZE NEWBORN FEEDING AND THE PROVISION OF LACTATION SUPPORT. IN GHANA, PATH IS LEADING A FOUR-YEAR (2020-2024) INITIATIVE, ADVANCED NEWBORN CARE IN GHANA: BEYOND MAKING EVERY BABY COUNT INITIATIVE (MEBCI 2.0), TO REDUCE PERINATAL MORTALITY IN FOUR HIGH-VOLUME REFERRAL HOSPITALS. IN 2020, MEBCI 2.0 ENGAGED WITH THE GHANA HEALTH SERVICE TO DESIGN ITS NEWBORN ACTION PLAN, MOBILIZE REGIONAL STAKEHOLDERS AND RESOURCES, AND DRIVE ADVOCACY AND POLICY ACTION. IN FOUR FOCUS COUNTRIES, PATH EMBARKED ON LESSONS LEARNED IN ESTABLISHING IN-PATIENT NEWBORN CARE, A PLATFORM FOR UNDERSTANDING AND SHOWCASING COUNTRY-LEVEL JOURNEYS TO PROVIDING CRITICAL CARE FOR SMALL AND SICK NEWBORNS. PATH ALSO LED THE ASSET TRACKER PROJECT TO DOCUMENT UPTAKE OF 14 KEY MNCHN ASSETS IN 81 COUNTDOWN TO 2030 COUNTRIES ACROSS AFRICA AND SOUTH ASIA. THROUGH KEY INFORMANT INTERVIEWS AND POLICY REVIEWS IN SEVEN TARGET COUNTRIES, PATH IDENTIFIED BARRIERS AND ENABLERS TO SCALE-UP AND PRESENTED AN INTERACTIVE DASHBOARD TO GUIDE STRATEGIES TO ACCELERATE COVERAGE. RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM DRIVES NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. IN 2020, PATH COMPLETED A SEVEN-YEAR PROJECT, MAXIMISING THE QUALITY OF SCALING UP NUTRITION PLUS (MQSUN+), WHICH ENGAGED MORE THAN 50 COUNTRIES AND THE GLOBAL SUN MOVEMENT SECRETARIAT IN DEMAND-DRIVEN, ADAPTIVE COLLABORATIONS. MQSUN+ EMPHASIZED COUNTRY-LED MULTISECTOR PLANNING, OFTEN IN FRAGILE CONTEXTS. IN THE LAST YEAR, SIX MQSUN+ COUNTRIES PRODUCED ENDORSED, COSTED PLANS TO REDUCE FOOD INSECURITY AND IMPROVE NUTRITION. OTHER ACTIVITIES IN 2020 INCLUDED PARTNERING WITH THE NATURE CONSERVANCY, DUKE UNIVERSITY, AND THE INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE ON USE OF ALTERNATIVE PROTEINS. WE ALSO PARTNERED WITH HARVESTPLUS TO EXPAND THE REACH OF BIOFORTIFIED CROPS. PATH CONTINUED OUR WORK ON THE BRIDGE COLLABORATIVE, A TRAILBLAZING, CROSS-DISCIPLINARY EFFORT OF MORE THAN 150 LEADING TECHNICAL EXPERTS FROM THE HEALTH, DEVELOPMENT, AND ENVIRONMENTAL SECTORS TO ADDRESS HUMAN AND PLANETARY HEALTH. IN CONJUNCTION WITH THE WILDLIFE CONSERVATION SOCIETY AND THE NATURE CONSERVANCY, THE BRIDGE COLLABORATIVE FOCUSED ATTENTION ON FOOD SYSTEMS AND THE INTERSECTION OF HUMAN AND PLANETARY HEALTH. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | IN 2020, MNCHN STAFF SERVED GLOBALLY IN LEADERSHIP ROLES RELATED TO COVID-19 AND THE PROTECTION OF WOMEN AND CHILDREN. WE PRESENTED (MOSTLY VIRTUALLY) AT KEY GLOBAL AND NATIONAL MEETINGS AND AUTHORED AND CONTRIBUTED TO HIGH-PROFILE PEER-REVIEWED JOURNAL ARTICLES, BOOK CHAPTERS, GLOBAL REPORTS, AND SYSTEMATIC REVIEWS. THESE EFFORTS ADVANCED THINKING ON BROAD, EFFECTIVE SOLUTIONS TO THE MOST PRESSING CHALLENGES IN MNCHN. SEXUAL AND REPRODUCTIVE HEALTH PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH (SRH) IS GUIDED BY THE KEY PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL PEOPLE. AND BECAUSE WE UNDERSTAND THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF WOMEN'S REPRODUCTIVE HEALTH, WE BUILD EVIDENCE AROUND TOOLS AND SERVICES THAT ARE BEST SUITED TO ADDRESS THEIR DIVERSE NEEDS AND CIRCUMSTANCES. WE SPECIALIZE IN REDUCING BARRIERS TO ACCESS AND INTRODUCING WOMAN-INITIATED PRODUCTS. PATH CHAMPIONS PEOPLE'S RIGHT TO MANAGE THEIR OWN SRH BY CREATING AND ADVANCING IMPROVED TOOLS AND PRACTICES THAT MAKE SELF-CARE FOR SRH POSSIBLE. IN 2020, WE CO-CREATED WITH THE GOVERNMENTS OF NIGERIA, SENEGAL, AND UGANDA THEIR FIRST-EVER NATIONAL SELF-CARE GUIDELINES. OUR INTEGRATED APPROACH INCLUDES ATTENTION TO CONTRACEPTION, CERVICAL AND BREAST CANCER, SEXUALLY TRANSMITTED INFECTIONS, AND A WOMAN'S RIGHT TO DECIDE WHETHER AND WHEN TO BECOME A MOTHER. OUR EFFORTS TO EXPAND ACCESS TO THE SELF-INJECTABLE CONTRACEPTIVE SUBCUTANEOUS DMPA (DMPA-SC, OR SAYANA PRESS) CONTINUED IN 2020. THE DMPA-SC ACCESS COLLABORATIVE WORKED WITH MINISTRIES OF HEALTH AND MULTISECTOR PARTNERS IN SIX COUNTRIES TO FACILITATE SELF-INJECTION INTRODUCTION AND SCALE-UP PLANNING FOR A RANGE OF CONTRACEPTIVES. DATA FROM 11 COUNTRIES SHOWED NEARLY 300,000 CLIENT VISITS FOR CONTRACEPTIVE SELF-INJECTION IN 2020; THE ACCESS COLLABORATIVE ALSO LAUNCHED AND SUPPORTED A CADRE OF "SELF-INJECTION AMBASSADORS" TO ADVANCE CONTRACEPTIVE SELF-INJECTION AND SELF-CARE OPTIONS MORE BROADLY. PATH ALSO WORKED TO IMPROVE THE PREVENTION, DETECTION, AND TREATMENT OF CERVICAL PRECANCER CAUSED BY INFECTION WITH HUMAN PAPILLOMAVIRUS (HPV). WE CONTINUED OUR PARTNERSHIP WITH THE MINISTRIES OF HEALTH IN GUATEMALA, HONDURAS, AND NICARAGUA TO SCALE UP HPV TESTING IN THE PUBLIC SECTOR. WE ALSO EVALUATED FOLLOW-UP AND TREATMENT STRATEGIES TO ENSURE WOMEN RECEIVE APPROPRIATE, COMPREHENSIVE CARE. AS THE PROJECT NEARED CLOSEOUT, WE WORKED TO TRANSITION ACTIVITIES TO THE MINISTRIES. GLOBALLY, PATH HELPED SHAPE STRATEGIES FOR LOW- AND MIDDLE-INCOME COUNTRIES AS PART OF WHO'S CALL FOR GLOBAL CERVICAL CANCER ELIMINATION. IN PERU, PATH CONTINUED TO IMPLEMENT A MODEL FOR EARLY DETECTION OF BREAST CANCER APPROPRIATE AND FEASIBLE FOR LOW- AND MIDDLE-RESOURCE SETTINGS. WE PARTNERED WITH THE MOH TO DESIGN AND IMPLEMENT A REAL-TIME DIGITAL PATIENT TRACKING SYSTEM FOR BREAST CANCER DETECTION. IN MYANMAR, PATH SUPPORTED THE CREATION OF THE NATIONAL STRATEGIC PLAN FOR REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH; DRAFTED A NATIONAL OPERATIONAL PLAN FOR CERVICAL PRECANCER SCREENING AND TREATMENT; CREATED A TRAINING CURRICULUM FOR HEALTH WORKERS ON SEXUAL AND REPRODUCTIVE HEALTH AND RIGHTS (SRHR), INCLUDING SELF-CARE INTERVENTIONS; HELD ADVOCACY WORKSHOPS; DEVELOPED SRHR AWARENESS TOOLKITS FOR PEOPLE LIVING WITH DISABILITIES; AND RESPONDED TO COVID-19 BY PARTNERING WITH LOCAL CIVIL-SOCIETY ORGANIZATIONS TO DISTRIBUTE INFECTION PREVENTION INFORMATION AND SUPPLIES IN REFUGEE CAMPS AND HARD-TO-REACH AREAS OF TWO STATES. IN INDIA, WE WORKED WITH THE ODISHA STATE GOVERNMENT TO LEVERAGE THE NATION'S POSTAL SERVICE TO DELIVER CONTRACEPTIVES BY MAIL-AND SO MAINTAIN ACCESS THROUGHOUT COVID-19. PATH CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF MORE THAN 540 PUBLIC AND PRIVATE ENTITIES AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND ACCESS TO CRITICAL SRH AND FAMILY PLANNING SUPPLIES AND SERVICES. NONCOMMUNICABLE DISEASES PATH IS AT THE FOREFRONT OF THE FIGHT AGAINST NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES AND CARDIOVASCULAR DISEASE, IN LOW-RESOURCE SETTINGS WORLDWIDE, WHERE THE BURDEN OF THESE DISEASES IS RISING DISPROPORTIONATELY. IN 2020, PATH CONTINUED TO SERVE AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES AND PRODUCTS. THIS GLOBAL, MULTISECTORAL COLLABORATION WORKS TO INCREASE ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LOW- AND MIDDLE-INCOME COUNTRIES. IN ADDITION TO GLOBAL ADVOCACY, THE COALITION LED THE DEVELOPMENT OF A FORECASTING TOOL FOR NCD MEDICINES AND PRODUCTS, PILOTED THE TOOL IN KENYA, AND LAID THE GROUNDWORK FOR ITS INTRODUCTION IN UGANDA. PATH IMPLEMENTED NCD PROJECTS IN GHANA, KENYA, AND VIETNAM THAT BUILD STRONGER PRIMARY HEALTH CARE SYSTEMS, SUPPLY CHAINS, AND DATA-DRIVEN DECISION-MAKING-ALL CRITICAL COMPONENTS OF HEALTH SYSTEM RESILIENCY: OUR EFFORTS IN GHANA INCLUDED SUPPLY CHAIN STRENGTHENING, MESSAGING TO SUPPORT THE COVID-19 RESPONSE, AND INTRODUCTION OF THE NCD NAVIGATOR-A FIRST-OF-ITS-KIND, LOCALLY MANAGED, NCD DIGITAL INFORMATION SYSTEM FOR RESOURCE PLANNING AND ALLOCATION. IN PARTNERSHIP WITH THE GHANA HEALTH SERVICE, PATH'S HEALTHY HEART AFRICA PROJECT CONDUCTED MORE THAN 500,000 BLOOD PRESSURE SCREENINGS AND LINKED THOSE DIAGNOSED TO TREATMENT. IN KENYA, PATH DEPLOYED A CUTTING-EDGE PROGRAM THAT ENABLES COMMUNITY AND HOUSEHOLD SCREENINGS FOR HYPERTENSION, REMOTE BLOOD PRESSURE AND BLOOD SUGAR MONITORING, TELEMEDICINE, COMMUNITY-BASED DRUG DELIVERY, AND ENHANCED DATA MANAGEMENT. WE TRAINED 2,815 HEALTH CARE WORKERS ON COVID-19 INFECTION PREVENTION AND CONTROL, WITH AN EMPHASIS ON PEOPLE LIVING WITH NCDS. AS THE MOH SEEKS TO IMPROVE THE NCD SUPPLY CHAIN IN PREPARATION FOR UNIVERSAL HEALTH COVERAGE, WE TRANSITIONED OWNERSHIP OF THE NCD NAVIGATOR TO THE MOH AND FINALIZED OUR KENYA NCD SUPPLY CHAIN REPORT. RECOMMENDATIONS FROM THE REPORT WERE ADOPTED IN THE KENYA NCD STRATEGY 2021-2025. OUR FOCUS IN VIETNAM WAS ON A PRIMARY HEALTH CARE MODEL THAT USES PUBLIC-PRIVATE PARTNERSHIPS, DIGITAL TOOLS, AND COMMUNITY HEALTH WORKERS TO SUPPORT SCREENING AND LINKAGES TO CARE; FOR EXAMPLE, WE BROKERED A PARTNERSHIP BETWEEN THE MOH, CO.OPMART (A LARGE, PRIVATE-SECTOR SUPERMARKET CHAIN), AND PATH TO LAUNCH THE FIRST-EVER SUPERMARKET BLOOD PRESSURE CHECKPOINT IN HO CHI MINH CITY. THE CHECKPOINT SCREENED ALMOST 1,000 PEOPLE BY THE END OF 2020, DEMONSTRATING THE FEASIBILITY OF THE APPROACH. FINALLY, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO NCD PREVENTION AND CARE. HEALTH SYSTEMS INNOVATION AND DELIVERY PATH'S HEALTH SYSTEMS INNOVATION AND DELIVERY (HSID) PROGRAM STRENGTHENS HEALTH SYSTEMS AND ENHANCES COUNTRY CAPACITY FOR DATA-DRIVEN DECISION-MAKING. OUR PORTFOLIO SERVES AS AN ORGANIZING MECHANISM FOR PATH PROJECTS AND INITIATIVES THAT STRENGTHEN HEALTH SYSTEMS. HSID'S HEALTH SYSTEMS ANALYTICS UNIT PROMOTES SYSTEMS THINKING. WITHIN AND OUTSIDE OF PATH, THE UNIT LEADS COMPLEX EVALUATIONS OF HEALTH PROGRAMS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES HEALTH TECHNOLOGY INTRODUCTION AND SCALE-UP, AND IMPROVES DATA QUALITY AND USE FOR DECISION-MAKING. IN 2020, AS PART OF THE GLOBAL FUND'S PROSPECTIVE COUNTRY EVALUATIONS, THE UNIT EVALUATED THE GLOBAL FUND'S BUSINESS MODEL IN THE DRC, GUATEMALA, SENEGAL, AND UGANDA-EXAMINING BARRIERS AND FACILITATORS TO IMPACT. THE GLOBAL HEALTH SECURITY TEAM CONTINUED TO INNOVATE FOR THE PREVENTION, DETECTION, AND CONTROL OF INFECTIOUS DISEASE OUTBREAKS. WITH SUPPORT FROM THE US CENTERS FOR DISEASE CONTROL AND PREVENTION (CDC), THE TEAM WORKED WITH NATIONAL LEADERS IN THE DRC, SENEGAL, TANZANIA, AND VIETNAM TO BUILD THEIR CAPACITY FOR EPIDEMIC PREPAREDNESS AND RESPONSE. THE TEAM ALSO WORKED AS A MAJOR SUBGRANTEE ON THE USAID IDDS PROJECT. OUR CROSS-ORGANIZATIONAL IMPACT TEAM FOR EPIDEMIC PREPAREDNESS AND RESPONSE REMAINED AT THE FOREFRONT OF THE EBOLA RESPONSE IN THE DRC-ENHANCING SURVEILLANCE, DETECTION, AND RESOURCE MOBILIZATION. OTHER EFFORTS INCLUDED STRENGTHENING ELECTRONIC HEALTH INFORMATION SYSTEMS, ADVANCING DIAGNOSTIC NETWORK CAPABILITIES, AND LINKING THIS WORK WITH DEVELOPMENT OF NEW DIAGNOSTICS, VACCINES, AND DATA TOOLS. COUNTRY PROGRAMS PATH'S COUNTRY PROGRAMS SUPPORT WORK RANGING FROM SMALL-SCALE PILOTS TO LARGE, MULTI-COUNTRY EFFORTS. IN 2020, WE OPERATED FULL-SCALE "COUNTRY" OFFICES IN THE DRC, CHINA, ETHIOPIA, INDIA, KENYA, MYANMAR, SENEGAL, TANZANIA, UGANDA, UKRAINE, VIETNAM, AND ZAMBIA, AS WELL AS SMALLER "PROJECT" OFFICES IN MANY OTHER COUNTRIES. OUR EXAMPLES THIS YEAR FOCUS ON INDIA, UGANDA, AND VIETNAM. |
| FORM 990, PART III, LINE 4A, DESCRIPTION OF PROGRAM SERVICE: | INDIA: PATH HAS WORKED IN INDIA FOR MORE THAN 20 YEARS TO IMPROVE HEALTH AND SAVE LIVES THROUGH INNOVATION AND COLLABORATION WITH LOCAL PARTNERS. PATH'S PROJECTS IN INDIA FOCUS ON TB, HIV, NEGLECTED TROPICAL DISEASES, VACCINES (BOTH DEVELOPMENT AND DELIVERY), AND REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH. IN 2020, PATH PROVIDED TECHNICAL SUPPORT TO THE GOVERNMENT OF INDIA TO EXPAND OUR AWARD-WINNING PUBLIC-PRIVATE MODEL FOR TB DIAGNOSIS AND TREATMENT TO 15 STATES ACROSS THE COUNTRY. OUR PIONEERING WORK IN RICE FORTIFICATION CONTINUED AS WELL, BRINGING LIFESAVING NUTRITION TO NEARLY 1 MILLION PEOPLE, INCLUDING MORE THAN 650,000 SCHOOLCHILDREN. WITH THE ONSET OF COVID-19, PATH IMMEDIATELY LEVERAGED OUR PROGRAMMATIC EXPERTISE AND WORKING RELATIONSHIPS WITH THE GOVERNMENT TO PREPARE HEALTH FACILITIES TO RESPOND TO THE DISEASE. WITH FUNDING FROM THE ROCKEFELLER FOUNDATION, PATH AND OUR PARTNERS WORKED WITH THE STATE GOVERNMENTS OF MAHARASHTRA AND PUNJAB TO IMPROVE ACCESS TO HIGH-QUALITY, AFFORDABLE TESTING FOR COVID-19 BY IMPLEMENTING NEWER DIAGNOSTIC TECHNOLOGIES AND NOVEL TESTING ALGORITHMS, AUTOMATING DATA ENTRY AND ANALYSIS, AND INCREASING HUMAN RESOURCE CAPACITY IN LABORATORIES. WE ALSO BEGAN IMPLEMENTING DECENTRALIZED GENE SEQUENCING PLATFORMS AT THE STATE LEVEL TO ACCELERATE IDENTIFICATION OF NEW VIRAL MUTATIONS AND VARIANTS. PATH'S INDIA TEAM IN 2020 CONTINUED OUR COLLABORATION WITH OTHER SOUTH ASIAN COUNTRIES; FOR EXAMPLE, WE SUPPORTED DEVELOPMENT OF A POINT-OF-CARE "SUITCASE LABORATORY" BASED ON RECOMBINASE POLYMERASE AMPLIFICATION FOR RAPID AND ACCURATE DIAGNOSIS OF KALA-AZAR AND POST-KALA-AZAR DERMAL LEISHMANIASIS IN BANGLADESH AND NEPAL. UGANDA: PATH'S UGANDA COUNTRY PROGRAM HAS BEEN PARTNERING CLOSELY WITH THE UGANDA MOH FOR MORE THAN 15 YEARS, IMPLEMENTING AN EVER-WIDER RANGE OF PROJECTS AIMED AT IMPROVING HEALTH. BELOW ARE A FEW HIGHLIGHTS FROM 2020. AS THE IDDS PROJECT LEAD IN UGANDA, PATH WORKED WITH THE UGANDA GOVERNMENT TO REVIEW EXISTING SURVEILLANCE SYSTEMS IN HUMAN AND ANIMAL HEALTH; SUPPORTED DEVELOPMENT OF NEW TESTING ALGORITHMS FOR PRIORITY ZOONOTIC DISEASES; DEVELOPED A STANDARDIZED QUALITY-CONTROL TOOLKIT; ASSESSED ANIMAL AND HUMAN SPECIMEN REFERRAL SYSTEMS; AND SUPPORTED LABORATORY TRAININGS. PATH'S LARGEST ADVOCACY AND PUBLIC POLICY PROJECT-OPERATING WORLDWIDE AND FUNDED BY THE BILL & MELINDA GATES FOUNDATION-CONTINUED TO FOCUS IN UGANDA ON IMMUNIZATION, PRIMARY HEALTH CARE, AND REPRODUCTIVE, MATERNAL, NEWBORN, CHILD, AND ADOLESCENT HEALTH. WITH COVID-19 DISRUPTING HEALTH SYSTEMS, PATH SUPPORTED THE MOH TO DEVELOP AND BROADLY DISSEMINATE MESSAGES ON COVID-19 PREVENTION AND THE CONTINUITY OF ESSENTIAL HEALTH SERVICES. PATH ALSO HELPED DRAFT THE UGANDA EXPANDED PROGRAM ON IMMUNIZATION RECOVERY PLAN FOR IMMUNIZATION SERVICES DURING COVID-19. OUR ADVOCACY FOR MEDICAL OXYGEN SCALE-UP IN UGANDA, LAUNCHED PRE-COVID-19, GAINED ADDED TRACTION IN THE PANDEMIC. PATH WORKED WITH THE KAMPALA CITY AUTHORITY AND TWO LEADING TELEVISION STATIONS TO AMPLIFY COVID-19 INFECTION PREVENTION AND CONTROL (IPC) MESSAGES; WE RECORDED A TALK SHOW THAT WAS HIGHLY PROMOTED AND FEATURED ON ONE OF THE TELEVISION STATIONS' TWITTER ACCOUNTS, WITH 1.2 MILLION FOLLOWERS. WITH FUNDING FROM THE HILTON FOUNDATION, PATH INTRODUCED ONSITE CHLORINE GENERATION FOR IPC AT HEALTH FACILITIES AND DONATED PERSONAL PROTECTIVE EQUIPMENT AND IPC MATERIALS TO 48 FACILITIES IN 11 DISTRICTS. WE PARTICIPATED IN A WATER FOR PEOPLE WORKING GROUP WITH INTERNATIONAL RESCUE COMMITTEE, WORLD VISION, AND THE US CDC TO IMPROVE WATER, SANITATION, AND HYGIENE IN HEALTH FACILITIES. AS PART OF A SUPPLY SYSTEMS INNOVATIONS GRANT, PATH COORDINATED THE SUCCESSFUL DISTRIBUTION AND INSTALLATION OF UPDATED COLD CHAIN EQUIPMENT IN TEN REGIONS OF UGANDA AND WORKED WITH THE MOH ON HPV VACCINE ACCESS AND COVERAGE. WE SUPPORTED WHO'S EFFECTIVE VACCINE MANAGEMENT INITIATIVE TO REVIEW STOCK STATUS, FORECASTING, COLD CHAIN EQUIPMENT MAINTENANCE, AND LOGISTICS PLANNING FOR COVID-19 AND OTHER VACCINES. TO PREPARE FOR COVID-19 VACCINE INTRODUCTION, PATH (WITH SUPPORT FROM GAVI, THE VACCINE ALLIANCE) DEVELOPED AN ADVOCACY AND ENGAGEMENT PLAN TO INCREASE STAKEHOLDER BUY-IN AND COMMUNITY ACCEPTANCE. WE THEN SUPPORTED THE SUCCESSFUL NATIONAL VACCINATION LAUNCH. THE BILL & MELINDA GATES FOUNDATION FAMILY PLANNING PROJECT AIMS TO IMPROVE THE HEALTH OF WOMEN AND GIRLS BY EXPANDING ACCESS TO RIGHTS-BASED FAMILY PLANNING, INCLUDING DMPA-SC, AN INJECTABLE CONTRACEPTIVE. IN UGANDA, PATH MOBILIZED FUNDING THAT LED TO THE CONTINUATION AND EVEN ACCELERATION OF FAMILY PLANNING EFFORTS, DESPITE CHALLENGES RELATED TO COVID-19. PATH WORKED WITH PARTNERS TO ENSURE DMPA-SC (INCLUDING SELF-INJECTION, WHERE APPROVED) WAS ACCEPTABLE TO USERS AND AVAILABLE AT AN AFFORDABLE PRICE AND AT A VARIETY OF SERVICE DELIVERY POINTS. FINALLY, THE HIV SELF-TESTING AFRICA (STAR) INITIATIVE (PHASE III) WORKED TO ESTABLISH THE STRUCTURES, SYSTEMS, AND OVERSIGHT NECESSARY FOR LONG-TERM SUSTAINABILITY OF THE HIVST MARKET IN UGANDA. COLLABORATING WITH THE MOH AND OTHER STAKEHOLDERS, THE STAR III TEAM DEVELOPED A FOUR-YEAR NATIONAL SCALE-UP PLAN FOR HIVST (2021-2024) AND MOBILIZED AND SUPPORTED A WHO PREQUALIFICATION TRAINING. THE TEAM MAPPED HIVST PARTNERS, TRAINED PEERS AND PROVIDERS, ASSESSED CURRENT REGULATIONS AND POLICIES, AND WORKING WITH THE NATIONAL DRUG AUTHORITY, DEVELOPED A POST-MARKET SURVEILLANCE PLAN. THE PROJECT REACHED NEARLY 16,000 CLIENTS, MAINLY THROUGH COMMUNITY DISTRIBUTION. VIETNAM: IN 2020, PATH CELEBRATED OUR 40TH ANNIVERSARY IN VIETNAM. THROUGH THE GLOBAL HEALTH SECURITY PARTNERSHIP FUNDED BY THE US CDC, PATH UPGRADED THE MOH'S ONLINE INFECTION SURVEILLANCE PORTAL, LAUNCHED A NEW ANTIMICROBIAL RESISTANCE (AMR) PORTAL, SUPPORTED DEVELOPMENT OF COVID-19 TRACKING AND SENTINEL SURVEILLANCE SYSTEMS, AND SUPPORTED TWO HOSPITALS IN QUALITY IMPROVEMENT IMPLEMENTATION. PATH ALSO ASSESSED VIETNAM'S ANIMAL HEALTH INFORMATION SYSTEM AS WELL AS THE LABORATORY CAPACITY, SPECIMEN REFERRAL, AND SURVEILLANCE SYSTEMS FOR ANIMAL AND HUMAN HEALTH. THROUGH THE FLEMING FUND, WE HELPED STRENGTHEN LABORATORY INFORMATION SYSTEMS AND BIOREPOSITORY MANAGEMENT, SUPPORTED HOSPITALS TO SUBMIT AMR REPORTS, DEVELOPED THE DEPARTMENT OF ANIMAL HEALTH'S AMR E-REPORTING PORTAL, AND ORGANIZED A WHONET WORKSHOP FOR THE DEPARTMENT AND THREE ANIMAL LABORATORIES. FOR COVID-19, PATH AND THE US CDC CONTRIBUTED TO THE NATIONAL GUIDELINES, DEVELOPED AN ONLINE SELF-ASSESSMENT FORM, AND SUPPORTED TRAINING FOR HOSPITALS AND 3,300 HEALTH CARE PROVIDERS. PATH ASSISTED THE MOH WITH COVID-19 VACCINE DEVELOPMENT AND INTRODUCTION EFFORTS AND SUPPORTED THE INTERNATIONAL VACCINE ACCESS CENTER TO PRODUCE COVID-19 VACCINE LOTS FOR USE IN CLINICAL TRIALS. THE USAID HEALTHY MARKETS PROJECT SCALED UP ACCESS TO HIVST AND HIV PREVENTION SERVICES, ENROLLING 6,177 NEW CLIENTS IN PRE-EXPOSURE PROPHYLAXIS AND REACHING MORE THAN 40,700 WITH HIV TESTING. PATH SUPPORTED A $2.5M+ PRIVATE-SECTOR INVESTMENT IN HIV RESPONSE AND BUILT THE CAPACITY AND SUSTAINABILITY OF KEY POPULATION ORGANIZATIONS. PATH ALSO SUPPORTED THE NATIONAL TB PROGRAM TO PILOT STOOL-BASED DIAGNOSIS OF PEDIATRIC TB AND CONSEQUENTLY UPDATE THE NATIONAL PEDIATRIC TB GUIDELINES. (SEE ALSO THE HIV AND TUBERCULOSIS SECTION.) THE INTRODUCING DIGITAL IMMUNIZATION INFORMATION SYSTEMS-EXCHANGE AND LEARNING PROJECT, FUNDED BY THE BILL & MELINDA GATES FOUNDATION, LAUNCHED AN E-LEARNING PLATFORM AND E-IMMUNIZATION CARD SYSTEM IN HANOI AND SON LA AND HELPED THE NATIONAL EXPANDED PROGRAM ON IMMUNIZATION TRANSITION TO PAPERLESS IN FOUR PROVINCES. FINALLY, TO COMBAT MALARIA, PATH CONDUCTED OPERATIONAL RESEARCH IN VIETNAM THAT PROVIDED EVIDENCE FOR ADOPTION OF G6PD TESTING. |
| FORM 990, PART III, LINE 4C, DESCRIPTION OF PROGRAM SERVICE: | WORK CONTINUED ON THE DATA USE PARTNERSHIP (DUP), WHICH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE ITS HEALTH INFORMATION SYSTEMS. IN 2020, DUP REFRESHED THE TANZANIA DIGITAL HEALTH INVESTMENT ROAD MAP AND RECEIVED APPROVAL FOR THE COUNTRY'S NEW CENTRE FOR DIGITAL HEALTH. DUP ALSO FINALIZED THE TANZANIA HEALTH ENTERPRISE ARCHITECTURE, A BLUEPRINT FOR IDENTIFYING AND ALIGNING IMPORTANT INTERRELATIONSHIPS BETWEEN THE COUNTRY'S DIGITAL SYSTEMS TO AVOID FRAGMENTATION, DUPLICATION, AND LACK OF INTEROPERABILITY. PATH BEGAN A NEW PROJECT, DATA USE ACCELERATION AND LEARNING, TO DOCUMENT AND AMPLIFY LEARNINGS FROM FIVE FOCAL COUNTRIES DIGITALIZING THEIR HEALTH SYSTEMS. THE INFORMATION WILL SUPPORT GOVERNMENTS, IMPLEMENTERS, POLICYMAKERS, AND FUNDERS AS THEY SHIFT THEIR FINANCING, GUIDANCE, AND PROGRAMMATIC APPROACHES TO IMPROVE THE USE OF DATA. PATH ALSO LAUNCHED THE HEALTH INSIGHT PLATFORM, A NEW DATA ANALYTICS AND VISUALIZATION SERVICE THAT USES BEST-IN-CLASS TOOLS TO ADVANCE DATA USE. LAST, PATH INCREASED PARTICIPATION IN HIGH-LEVEL COALITIONS, INCLUDING TRANSFORM HEALTH, THE LANCET/FINANCIAL TIMES JOINT COMMISSION ON GOVERNING HEALTH FUTURES 2030, AND THE DIGITAL CONNECTED CARE COALITION. |
| FORM 990, PART VI, SECTION B, LINE 11B | THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRINCIPAL FINANCIAL OFFICER SIGNED THE FORM. |
| FORM 990, PART VI, SECTION B, LINE 12C | PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS). THE MOST RECENT MAJOR REVIEW WAS COMPLETED BY THE BOARD COMPENSATION COMMITTEE IN 2020. AT THE REQUEST OF THE BOARD, PATH ENGAGED MERCER (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO AND EXECUTIVE TEAM MEMBERS. MERCER USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE MERCER REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE EXECUTIVE TEAM MEMBERS. ADDITIONALLY, MERCER REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE. |
| FORM 990, PART VI, SECTION C, LINE 19 | PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PATH VACCINE SOLUTIONS | ||||||||||||||
| 2201 WESTLAKE AVENUE | SEATTLE | WA | 98109 | 830431851 | ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN | WA | 501(C)(3) | LINE 12A, I | PATH | Yes (1) | ||||
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||||||||||||||
| EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH | 501(C)(3) | PATH | Yes (1) | 207 ROUTE DE FERNEY 1218 LE GRAND-S | GENEVA | SZ | SZ | |||||||
| PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH -KENYA | ||||||||||||||
| EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH | 501(C)(3) | PATH | Yes (1) | ACS PLAZA 4TH FL LENANA RD PO BOX | NAIROBI | KE | KE | |||||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | Yes (1) | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (1) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | 0 | SharingOfFacilitiesInd |
| Paid Employees Sharing | 0 | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (3 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| PATH VACCINE SOLUTIONS | ||
| C | $4,386,562 | FMV |
| PATH VACCINE SOLUTIONS | ||
| B | $46,272 | FMV |
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||
| B | $4,534,968 | FMV |